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GENERAL INTRODUCTION 
Coronary artery disease (CAD) is the leading cause of mortality in the Western 
world. Complications of myocardial infarction are the most important cause of 
mortality in patients with CAD 1. Therefore, risk assessment for future cardiac 
events is an important clinical question in these patients. Multiple prognostic 
parameters including infarct size, ischemia detection, left ventricular ejection 
fraction (LVEF) and left ventricular (LV) cardiac volumes have been introduced for 
management and follow-up of patients with CAD. During the past decades 
radionuclide myocardial perfusion imaging (MPI) using 201-thallium, first with 
planar and later with single photon emission computed tomography (SPECT) 
images, has proven to be of high diagnostic and prognostic utility in predicting 
future cardiac events 2,3. Detecting CAD using radionuclide MPI is based on the 
visualisation of the coronary flow reserve. The coronary blood flow is primarily 
regulated at the arteriolar level. In normal epicardial arteries a minimal resistance 
to flow is observed 4. During exercise, the myocardial oxygen demands increase, 
which results in arteriolar vasodilatation allowing blood flow to increase 2-fold to 3-
fold 5. In patients with CAD, many factors may increase epicardial resistance, 
including the severity and length of the stenosis 6,7, the presence of sequential 
arterial lesions 8 and intrinsic epicardial vasomotion 9. Regardless of the mechanism 
of vascular resistance altering, the resting myocardial perfusion is generally 
maintained even when obstructions occlude 80-90% of the arterial cross-sectional 
area 6. The capability for further hyperaemia during physical exercise or during 
pharmacological stress is however decreased. During exercise, the relative 
myocardial radionuclide concentration will be greater in the vascular beds supplied 
by a normal coronary artery compared with those perfused by an artery with a 
severe obstruction.  
 
Since the late eighties 99m-technetium labelled perfusion tracers were developed 
and showed to be as valuable as 201-thallium for perfusion imaging 10,11. The 
favourable imaging characteristics (high count density) of 99m-technetium make it 
possible to perform an electrocardiogram-gated cardiac SPECT during the 
acquisition of myocardial perfusion 12, which not only improves the specificity for 
the detection of CAD 13, but also enables to assess simultaneously LV functional 
parameters including LVEF and LV volumes 14,15. It is well-known that LV functional 
data provide prognostic information in CAD patients. One of the most powerful 
prognostic parameters in patients with CAD is the LVEF. This measure is not a pure 
measure of intrinsic myocardial contractility since its value depends on and is 
affected by other parameters, such as heart rate and cardiac loading conditions.  
Despite this, LVEF has been found to be an extremely useful correlate of survival 
and thus a determinant of therapeutic decisions in a broad variety of cardiovascular 
disorders 16. Multiple studies demonstrated the prognostic value of this parameter 
using different imaging modalities 17-21. In particular both resting and exercise LVEF 
determined by radionuclide angiography (RNA) and other techniques are major 
determinants of long-term survival in patients with known CAD.  Since the 
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development of RNA, multiple studies have reported its important prognostic value 
as a non-invasive tool 19,20,22,23. However, during the last decade short and long-
term survival rates after acute myocardial infarction improved markedly with the 
introduction of new reperfusion strategies 24. This made it necessary to re-evaluate 
the prognostic value of LVEF estimated by RNA. In 1998, Shaw et al. 21 showed 
that also in the present era, LVEF determined using RNA at rest and during peak 
exercise provided information highly predictive of cardiac death (both p < 0.0001) 
in 863 consecutive patients with known CAD, of which 68% had a prior history of 
myocardial infarction.  
Not only the LVEF, also LV cardiac volumes assessment provides information for the 
prediction of future cardiac events and cardiac death. Already in 1987, White et al. 
found that cardiac volumes and most importantly LV end-systolic volumes, in this 
study assessed by X-ray left ventriculography during catheterisation, had a high 
predictive value for future cardiac death during a mean follow-up of 78 months in 
605 male patients after a first or recurrent acute myocardial infarction (х2 = 82.9, 
p< .001). Using the same technique, a study by Hamer et al. showed comparable 
results in a population of 193 patients after coronary artery bypass grafting. The 
invasiveness of catheterisation and the assumption of an ideal ellipsoidal geometry 
of heart chambers to estimate cardiac volumes makes the assessment of 
myocardial function during catheterisation less suitable for follow-up of patients 
with known CAD 25. Therefore, non-invasive imaging techniques are generally 
preferred for cardiac functional imaging.  
A large and growing variety of non-invasive imaging methods is available to assess 
global LV function and volumes, including echocardiography, radionuclide 
techniques (RNA and myocardial gated SPECT) and cardiac magnetic resonance 
imaging (MRI). Each of these techniques is characterised by a variety of strengths 
and pitfalls. The ideal technique for imaging global LV function should not only offer 
highly accurate and reproducible measurements of both LVEF and LV volumes but 
also be time and cost efficient, non-invasive and widely available. Currently global 
LV function is, due to clinical circumstances, most commonly investigated by 
transthoracic echocardiography, which is widely available, readily accessible and 
inexpensive.   
M-mode echocardiography and 2-dimensional echocardiography, like all not truly 3-
dimensional (3D) techniques, assume an ideal ellipsoidal geometry of the heart 
chambers to estimate cardiac volumes. After myocardial infarction though, LV 
shape may be altered radically both due to infarct extension and the following 
remodelling process 26, which makes it difficult to make a good estimation of 
cardiac volumes and LVEF when assuming an ideal ellipsoid heart shape. Truly 3D 
techniques, like 3D echocardiography and 3D MRI but also gated SPECT, do not 
require assumptions of a normal heart shape for accurate estimation of LV 
volumes.  All these tomographic methods have shown to be highly accurate and 
highly reproducible for the measurement of LV volumes and LVEF.  
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Cardiac MRI is, due to its high resolution and intrinsic 3D tomographic acquisition 
considered the ideal imaging modality for measuring cardiac volumes and changes 
in cardiac volumes over time.  However there are few studies investigating the 
prognostic value of these volumetric data. Wu et al. investigated a small population 
of 44 patients early after myocardial infarction and found that there was a 
significant rise in LV end-diastolic and end-systolic volumes over a 6 month period 
post infarction in patients with a microvascular obstruction compared to patients 
without obstruction 27. In an even smaller study, Sandstede et al. investigated 12 
patients after myocardial infarction both with resting and stress cardiac MRI 28. 
Patients who had a lower LV end-systolic volume and a higher LVEF on stress 
imaging compared to rest imaging had a greater improvement of global LV function 
after revascularisation than patients with a higher LV end-systolic volume and a 
lower LVEF. Up-to date, there are however no large studies focussing on the long 
term prognostic value of cardiac MRI. 
Using myocardial gated SPECT, Sharir et al. showed in a retrospective study in a 
large population of 1680 patients who underwent rest 201-thallium/ stress 99m-
technetium sestamibi that functional data obtained during gated MPI provide 
incremental prognostic information above myocardial perfusion data 29. 
 
Prognosis in CAD patients 
 
Prognosis in CAD patients is determined by clinical risk factors, the extent and 
severity of CAD and the degree of LV dysfunction. Using gated SPECT, it is possible 
to visualise extent and severity of CAD and LV function routinely. In this thesis, we 
used myocardial gated SPECT for functional imaging because this technique has 
proven to be accurate, operator independent and reproducible for the assessment 
of global LV function. Another advantage of myocardial gated SPECT imaging is 
that the functional data can be assessed at little or no extra cost during a 
myocardial perfusion study. In October 1998, we started collecting data for the 
Ghent Gated SPECT Database. Since then, clinical data, perfusion SPECT and 
functional SPECT data in patients referred routinely for 2 day stress-rest gated 
SPECT imaging in the Ghent University Hospital are being collected prospectively.  
In this thesis we focussed on the outcome of patients with CAD and LV dysfunction 
and on the elderly population. We selected these patient populations because they 
become a growing proportion of the patients in the cardiology department: 
- The proportion of patients with CAD and LV dysfunction is growing as a result of 
increasing life expectancy and a longer survival of patients with CAD in particular. 
- Similarly, due to aging of the population and better medical and revascularisation 
treatment, more and more elderly patients are seen for diagnostic cardiac work-up.  
 16
GENERAL INTRODUCTION 
Outline of this thesis 
 
In the first chapter, we investigated relevant technical issues considering cardiac 
gated SPECT imaging. 
 
In chapter 2, we investigated the value of combined perfusion and function imaging 
in patients with CAD and poor LV function in the prediction of future cardiac events.  
Secondly, patients with CAD and a severely depressed LV function are possible 
candidates for resynchronisation treatment. In these patients, we investigated the 
prevalence of non-viable tissue in the inferolateral wall, the region were pacing 
leads for cardiac resynchronisation treatment are commonly placed. Since non-
viable tissue is electromechanically non-functional (30), placement of the lead in 
the inferolateral region could lead to ineffective pacing in these patients (31).  
 
In chapter 3, we investigated the predictive value of combined perfusion and 
function imaging for cardiac death and all-cause mortality in the elderly population, 
a growing proportion of the patients in the cardiology department.  
Amino-terminal pro brain natriuretic peptide (Nt-proBNP) is a valuable tool in the 
diagnosis and has prognostic value in CAD patients. It is known that increasing age 
is associated with higher serum brain natriuretic peptide levels.  We investigated 
which clinical, myocardial perfusion and function parameters are determinants of 
Nt-proBNP in elderly patients with stable CAD. 
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Technical aspects of cardiac gated SPECT imaging
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INTRODUCTION 
1.1 Introduction 
 
In the first chapter we investigated technical variabilities concerning gated 
myocardial and bloodpool single photon emission computed tomography (SPECT) 
imaging. 
Myocardial gated SPECT is increasingly used for left ventricular (LV) functional 
imaging in coronary artery disease (CAD) and has been validated against other 
cardiac imaging modalities 1-8. However, little is known about the variability of LV 
functional measurements using this imaging modality. Serial reproducibility of the 
measurement of LV volumes and ejection fraction (LVEF) by gated SPECT has been 
shown to be very good on repeated processing of the same gated raw data 7. Also 
global LV kinetic parameters assessed by repeated scanning (twice scanning a 
patient after a single tracer injection) using a 99m-technetium ligand has been 
shown to be highly reproducible 9. However, when measurements in patients are 
performed to monitor changes over time in LV dimensions and function, the 
difference between two measurements is subject to interstudy variability. This 
interstudy variability may be of technical and biological origin. This variability 
should be assessed in serial tests rather than by repeat analysis of a single image 
10. In the first part of this chapter we investigated the day- to day variability of 
myocardial gated SPECT imaging in CAD patients with a reduced LVEF. The 
knowledge of this variability is important since gated SPECT is routinely used for 
follow-up over time of LV perfusion and function in these patients. 
 
In the second part, we studied the agreement between different software 
algorithms for the evaluation of global left and right ventricular function in 
bloodpool SPECT imaging and compared these with planar bloodpool imaging. 
Recently, different programs are being developed to process tomographic 
radionuclide ventriculography 11-14. These programs provide left and right 
ventricular volumes and ejection fractions, but validation of these parameters, 
mostly of the right ventricle, remains scarce. We therefore wanted to compare 
LVEFs calculated from planar radionuclide ventriculography with values from 
tomographic radionuclide ventriculography, calculated by four different software 
programs: QBS, QUBE, 4D-MSPECT and BP-SPECT. Furthermore, we compared left 
ventricular and right ventricular stroke volumes, calculated from tomographic 
radionuclide ventriculography from QBS, QUBE and BP-SPECT, as a method of 
validation of left ventricular and right ventricular volumetric parameters. 
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Abstract 
 
Background: Although myocardial gated SPECT is routinely used for functional 
measurements in patients with coronary artery disease (CAD) and heart failure, 
day-to day variability of left ventricular ejection fraction (LVEF), left ventricular  
(LV) volumes and global perfusion scoring have not yet been investigated. 
Methods: In 20 consecutive patients with CAD and a LVEF < 40% who routinely 
underwent a resting tetrofosmin gated single photon emission computed 
tomography (SPECT) study, we performed an additional gated SPECT at rest 1-5 
days later under the same circumstances. LV volumes and LVEF were calculated 
from the gated SPECT data by commercially available software (QGS®). Myocardial 
perfusion was scored visually using a 20-segment, 5 point score method. For global 
LV function and perfusion, agreement between data was investigated using Bland-
Altman plotting.  
Results: The 95 % limits of agreement found by Bland-Altman analysis were –0.9 ± 
6.0 % for LVEF, +3 ± 20 ml for LVEDV and +4 ± 20 ml for LVESV.  
Conclusion: In CAD patients with a LVEF < 40 %, day-to day variability of 
measurements of global myocardial function and perfusion is quite similar as inter- 
and intraobserver variability. Day-to day variability of global LV functional 
parameters obtained by gated cardiac SPECT is fairly small, which indicates that 
myocardial gated SPECT can be used in daily clinical practice to determine changes 
in global LV function and perfusion over time in patients with a diminished LV 
function. 
 
Introduction 
 
Global left ventricular (LV) functional parameters assessed by myocardial gated 
Single Photon Emission Computed Tomography (SPECT) are routinely used for 
follow-up in patients with heart failure due to coronary artery disease (CAD) 1,2. The 
accuracy of global LV functional indices calculated by gated cardiac SPECT has been 
validated against many other imaging techniques like cardiac magnetic resonance 
imaging (MRI) 3,4, echocardiography 5,6, planar RNA 6-9 and contrast angiography 
during catheterisation 10. Serial reproducibility of the measurement of LV volumes 
and left ventricular ejection fraction (LVEF) by gated SPECT has been shown to be 
very good on repeated processing of the same gated raw data 9. Also global LV 
kinetic parameters assessed by repeated scanning (twice scanning a patient after a 
single tracer injection) using a 99mTechnetium (99mTc) ligand has been shown to be 
highly reproducible 11. However, when measurements in patients are performed to 
monitor changes over time in LV dimensions and function, the difference between 
two measurements is subject to interstudy variability. This interstudy variability 
may be of technical and biological origin. Technical factors include variability in data 
acquisition and analysis. Biologic variations such as loading conditions, adrenergic 
drive, heart rate, may cause variations in LV dimensions and function. This 
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variability should be assessed in serial tests rather than by repeat analysis of a 
single image 12. A real day-to day variability of global LV functional parameters 
assessed by gated SPECT has never been investigated in patients with a reduced 
LVEF. However, it is of significant clinical importance to have an idea of the day-to 
day variability when evaluating a possible deterioration or amelioration of functional 
and perfusional parameters over time or after an intervention such as coronary 
artery bypass grafting or percutaneous transluminal coronary angioplasty. The aim 
of this study is to investigate the day-to day variability of global functional and 
perfusional LV parameters assessed with myocardial gated SPECT in patients with a 
severely depressed LV function due to CAD. 
 
Materials and methods 
 
Patient population 
 
In 20 patients (17 males/ 3 females; mean age 69 ± 8 y, mean body mass index 28 
± 8) with known CAD and a resting LVEF < 40 % calculated by Quantitative Gated 
SPECT software (QGS®, Cedars-Sinai, Los Angeles) 9 who routinely underwent a 
resting 99mTc tetrofosmin gated SPECT study (study 1) in a 2 day high dose 
stress/rest protocol, we performed an additional gated SPECT under the same 
circumstances. The patients returned for a repeat myocardial gated SPECT study in 
resting condition 1-5 days after the first study (mean 3.65 days) (study 2). The 
injected dose and acquisition protocol was the same in study 1 and 2. Patients 
were included when they had known CAD and a resting LVEF < 40 % determined 
by myocardial gated SPECT. 
Fourteen patients (70 %) had a history of myocardial infarction and 8 (40%) a 
history of coronary artery bypass grafting. One patient was in atrial fibrillation but 
with a ventricular rhythm that made adequate electrocardiogram (ECG) gating 
possible. Two patients showed left bundle branch block on the resting ECG. 
Regarding medication, 12 patients (60%) were on beta-blockers and 18 (90%) on 
Angiotensin Converting Enzyme Inhibitors. Mean heart rate was 71 ± 12 beats/’ in 
study 1 versus 66 ± 12 beats/’ in study 2 (p = not significant). Mean systolic blood 
pressure was 127  ± 20 mmHg and mean diastolic blood pressure was 79 ± 9 
mmHg. The clinical status remained unchanged between the first and the second 
scan for all patients. 
The study was approved by the local Ethics Committee of the Ghent University 
Hospital. Written informed consent was obtained from all included patients prior to 
the study, after the nature of the study had been fully explained. 
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Gated SPECT Acquisition and reconstruction 
 
In resting condition we administered 900 Mega Becquerel (MBq) (25 milli Curie) of 
99mTc tetrofosmin intravenously in both study 1 and 2. Gated SPECT acquisition was 
performed over 360° (120 sectors of 3°) and was started between 30 and 45 
minutes after tracer injection using a triple-headed camera (Picker Prism 3000, 
Marconi, Philips, Cleveland, Ohio) with a low energy all purpose collimator. In this 
way 40 step-and-shoot images were acquired for each detector, with 30 s per step 
and intervals of 3°, a matrix size of 64 x 64. Acquisitions were gated for 8 frames 
per cardiac cycle. Gated SPECT data were reconstructed using filtered back 
projection (ramp filter) over 180° (selected reconstruction angle from -45° to +135 
°) and post-filtered using a low pass filter (order 5, cut-off frequency .21). There 
was a 20 % acceptance window around the 140 keV photo peak. Attenuation 
correction, background subtraction and beat rejection were not performed. The left 
ventricle was reoriented manually by a physician to obtain short axis, horizontal 
long axis and vertical long axis gated and ungated images. Data of study 1 and 2 
were processed independently. To determine the interobserver variability of LVEF 
and LV volumes, data of study 1 were reconstructed and reoriented independently 
by a second physician using the same reconstruction parameters, but without 
knowledge of the reorientation of the first physician. To determine the 
intraobserver variability, raw data of study 1 were reprocessed one month after the 
first processing by the same physician who processed study 1.  
 
Calculation of LV volumes and LVEF 
 
The QGS® software automatically calculates left ventricular volumes (including left 
ventricular end diastolic volume [LVEDV] and left ventricular end systolic volume 
[LVESV]) by summing the area of the short axis slices following the Simpson rule 9. 
LVEF is calculated by the formula [LVEDV-LVESV/ LVEDV].  
 
Grading of myocardial perfusion 
 
Rest perfusion scans were visually graded on polar plots of the ungated data using 
a 20 segment, 5 point scoring method (0: normal uptake, 4 absent uptake) 13,14. 
Summed perfusion score (SPS) at rest 13, which can be considered global indices of 
resting myocardial perfusion, were calculated by summing the perfusion score of 
the 20 segments for each scan. No semi-quantitative software was used for 
perfusion scoring. Intraobserver, interobserver and day-to day variability was 
calculated for the SPS. Intra- and interobserver variability was determined by 
rescoring the data of the first study of every patient. 
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Statistical analysis 
 
Bland-Altman analyses were performed to determine the 95 % limits of agreement 
for LVEF, LVESV, LVEDV and SPS 15. Measurements of LVEF, LVEDV and LVESV 
were normally distributed (tested by the Shapiro-WilkTest 16). Differences of mean 
were investigated using a Student t-test. 
 
Results 
 
QGS® succeeded in automatic edge detection and calculation of LV volumes and 
LVEF in 37/ 40 scans (92%). In 3 scans were automatic border detection failed due 
to high extra cardiac activity, masking of the extra cardiac activity on the short axis 
images was necessary to make accurate automatic border detection by the QGS® 
software possible. The manual border detection tool provided by the QGS® 
software program was not used. Mean values for global LV function and perfusion 
are shown in table 1. Values ranged from 18-38 % for LVEF, from 101-377 ml for 
LVEDV and from 70-277 ml for LVESV (study 1). No significant difference was 
found between the samples. 
 
a) Global LV function 
 
Bland-Altman plots of the day-to day variability of LVEF, LVEDV and LVESV are 
shown in figure 1. The 95 % limits of agreement for global LV function for day-to 
day, inter and intraobserver variability are shown in table 2. As expected 95 % 
limits of agreement were broader for day-to day than for interobserver variability 
and broader for interobserver variability than for intraobserver variability. For day-
to day variability 95 % limits of agreement were ± 6.0 % for LVEF and ± 20 ml for 
both LVEDV and LVESV.  
 
b) Global perfusion scoring 
 
Bland-Altman plotting of day-to day variability of SPS is shown in figure 2. The 95 
% limits of agreement for day-to day, inter and intraobserver variability are shown 
in table 2. The SPS scores ranged from 21-70 in study 1 and from 19-67 in study 2. 
Eighty is the theoretically maximum SPS score in a 20 segment, 5 point scoring 
method like we used. Similar as for global functional parameters, 95 % limits of 
agreement were broader for day-to day than for interobserver variability and 
broader for interobserver variability than for intraobserver variability. For day-to 
day variability of the SPS, 95 % limits of agreement were ± 9.1 on Bland-Altman 
plotting in this patient population with severe perfusion abnormalities. 
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Discussion 
 
In this study we showed that day-to day variability of global LV functional indices 
assessed by gated SPECT in patients with severe heart failure due to CAD is 
reasonably small. We found 95 % limits of agreement on the Bland-Altman plot 
were  ± 6% for LVEF and  ± 20 ml for LVEDV and LVESV. To our knowledge, there 
are no full text articles and only one abstract by Johnson et al. 17 where a real day-
to day variability (where the acquisition was investigated by scanning on 2 separate 
days after tracer injection in resting state) for gated SPECT measurements was 
investigated. Johnson et al. found 95 % limits of agreement on the Bland-Altman 
plot were ± 5.3 % for LVEF, ± 12 ml for LVEDV and ± 13 ml for LVESV. The 
population (16 patients) investigated by this group however was much less uniform 
and patients with a normal LV function were also included. Patients with more 
extensive CAD, like the population we investigated, frequently show cardiac regions 
with severely diminished tracer accumulation. The myocardium of these patients is 
more difficult to realign and it can be more difficult for the automatic software to 
define accurately the myocardial border in large areas with severe hypoperfusion. 
Therefore, it is expected that variability of functional measurements will be larger in 
patients with extensive CAD than in a less severely diseased population. Up till now, 
variability of gated SPECT measurements had only been investigated by repeated 
scanning after a single tracer injection (twice consecutively scanning on the same 
day after a single tracer injection). Using 99mTc bound ligands, this variability is 
small after stress, with 95 % limits of agreement being ± 5.3-6.4 % for LVEF , ± 
14.1-14.4 ml for LVEDV and only ± 9.4-11.2 ml for LVESV 11,18-20. There are to our 
knowledge no articles investigating the variability of measurements of global LV 
function in resting condition . Using 201Tl, repeated scanning (1 tracer injection, 
twice consecutively scanning on the same day) has broader levels of agreement for 
global LV functional measurements with 95 % limits of agreement being ± 12 % 
for resting LVEF, ± 29 ml and ± 19 ml for LVEDV and LVESV respectively. This 
makes gated myocardial perfusion SPECT using 201Tl less suitable for follow-up of 
alterations in global LV function in CAD patients 21.  
When raw gated SPECT data study are reprocessed by the same observer 
(intraobserver variability) or by a different observer (interobserver variability), 
correlation is very high between measurements of global LV function 22. However, a 
high correlation is logical when processing two consecutive times the same volumes 
by a single technique. It is thus not appropriate to use correlation or regression 
analysis when measuring agreement. Few studies performed Bland-Altman plotting 
which makes it impossible to make a good comparison with our results for intra- 
and interobserver variability. The interobserver variability was smaller in the study 
performed by Hyun et al. with 95 % limits of agreement for post stress LVEDV 
being ± 9 ml (versus ± 20 ml in our study) and ± 8 ml for LVESV (versus ± 17 ml 
in our study) 11. Limits of agreement for LVEF though were slightly narrower in our 
study (± 4.4 % versus ± 3.0 % in our study). These broader limits of agreement 
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for LV volumes can be explained by the fact that the population described in our 
paper had a much more severely depressed LV cardiac function (mean LVEF 41 ± 
14 % versus 28 ± 6 % in our study), had larger cardiac volumes (mean LVEDV 120 
± 52 ml versus 231 ± 77 ml in our study) and more severe perfusion abnormalities 
in the LV wall. These severe perfusion abnormalities may cause more problems to 
accurately realign the myocardium manually during processing and may possibly 
also influence the accuracy of the definition of the endocardial cavity by the 
automatic software.  
It is important to know the intra- and interobserver variability of a technique. 
However, when measurements in patients are performed to monitor changes over 
time in LV dimensions and function for follow-up of remodeling in CAD, the 
difference between two measurements is not only subject to variability of technical 
origin, but also of biological origin. Technical factors include variability in data 
acquisition and analysis. Biological variations, such as variation by loading 
conditions, adrenergic drive and heart rate, may also cause variations in LV 
dimensions and function 12. We preferred to perform a repeat study on an alternate 
day to investigate the real day- to day variability of the technique, because this 
situation reflects the daily clinical practice in the most accurate manner. In general 
one would expect day-to day variability to be at least as high as the variability of a 
repeated acquisition using a single tracer injection. This study shows that day-to 
day variability of global LV functional parameters obtained by gated cardiac SPECT 
is quite similar as inter- and intraobserver variability. Because 95 % limits of 
agreement for day-to day variability are reasonably small both for LVEF and LV 
volumes measured by gated SPECT, this technique can be used to monitor changes 
in LV function over time.  
In table 3 we compared our data with the 95 % limits of agreement of day-to day 
variability of studies of other imaging techniques that investigated intraobserver, 
interobserver and day-to day variability in heart failure patients 23-25.  Due to its 
intrinsic higher resolution, MRI is considered the reference method for global LV 
function. However there is a comparable intra- and interobserver variability for 
gated SPECT and even smaller limits of agreement for LVEF. This can be explained 
by the fact that processing of gated SPECT data is almost entirely automatic and 
thus much less susceptible to variability caused by the processing. Planar RNA is 
very reproducible for LVEF, but LV volumes are more difficult to measure by this 
technique.  
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Conclusions 
 
Day-to day variability of global indices of cardiac function assessed by 99mTc 
tetrofosmin myocardial gated SPECT is fairly small in patients with a diminished LV 
function due to CAD. The 95 % limits of agreement were –0.9 ± 6.0 % for LVEF, 3 
± 20 ml for LVEDV and 4 ± 20 ml for LVESV. This makes gated myocardial SPECT 
useful for follow-up of alterations in global cardiac function over time due to 
medical treatment or evolution of CAD. 
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Tables 
 
Abbreviations in the tables 
 
3D-echo: 3- dimensional echocardiography 
LVEDV: left ventricular end diastolic volume  
LVEF: left ventricular ejection fraction 
LVESV: left ventricular end systolic volume 
MRI: (cardiac) MRI 
Ns: not significant 
RNA: radionuclide angiography 
SPECT: single photon emission computed tomography 
SPS: summed perfusion score 
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Table 1 
 
Mean ± standard deviation of global LV indices and summed perfusion score values 
 
 
 
 
 Study 1 Study 2 P 
 Mean Range Mean Range  
LVEF 27.9 ± 5.8 % 18-38 % 27.5 ± 5.3 % 19-38 % Ns 
LVEDV 231 ± 77 ml 101-377 ml 234 ± 80 ml 84-366 ml Ns 
LVESV 169 ± 65 ml 70-277 ml 172 ± 66 ml 59-281 ml Ns 
SPS 42 ± 14 21-70 42 ± 15 19-67 Ns 
 
Table 2 
 
The 95 % limits of agreement for global LV functional and perfusional measurements 
 
  95 % limits of agreement 
 intraobserver - 0.15 ± 1.6 % 
LVEF interobserver - 0.60 ± 3.0 % 
 day-to-day - 0.85 ± 6.0 % 
   
 intraobserver + 0.6 ± 14 ml 
LVEDV interobserver - 3.8 ± 22 ml 
 day-to-day + 2.7 ± 20 ml 
   
 intraobserver + 0.4 ± 12 ml 
LVESV interobserver - 1.6 ± 17 ml 
 day-to-day + 3.8 ± 20 ml 
   
 intraobserver - 0.1 ± 4.1 
SPS interobserver - 0.8 ± 5.4 
 day-to-day + 0.5 ± 9.1 
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Table 3 
 
The 95 % limits of agreement for variability of global LV functional indices using different imaging 
techniques 
 
 
 
 
 
  3D-echo 23 MRI 24 RNA 25 Gated SPECT
 Intraobserver 5.6 % 4.4 % 2.4 % * 1.6 % 
LVEF Interobserver 7.6 % 6.6 % 3.0 % * 3.0 % 
 day-to-day 1.8 % 5.0 % 2.0 % 6.0 % 
      
 Intraobserver 29 ml 12 ml - 14 ml 
LVEDV Interobserver 32 ml 24 ml - 22 ml 
 day-to-day 11 ml 15 ml - 20 ml 
      
 Intraobserver 27 ml 13 ml - 12 ml 
LVESV Interobserver 21 ml 19 ml - 17 ml 
 day-to-day 7 ml 13 ml - 20 ml 
 
 
*data from pts with a normal + abnormal LVEF  
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Figures 
 
Abbreviations in the figures 
 
Diff. : Difference 
LVEF : left ventricular ejection fraction 
LVEDV : left ventricular end-diastolic volume 
LVESV : left ventricular end-systolic volume 
SPS: summed perfusion score 
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Figure 1 
 
Bland-Altman plot: Day-to day variability of LVEF, LVEDV and LVESV by gated SPECT 
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Figure 2 
 
Bland-Altman plot of SPS of study 1 and 2 
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Abstract 
 
Background: Left and right ventricular ejection fractions (LVEF and RVEF) and end-
diastolic and end-systolic volumes (LVEDV, RVEDV, LVESV and RVESV) can be 
calculated from tomographic radionuclide ventriculography (TRV). We wanted to 
validate and compare these parameters from four different TRV software’s (QBS, 
QUBE, 4D-MSPECT and BP-SPECT). 
Methods: We compared LVEF from planar radionuclide ventriculography (PRV) with 
LVEF from TRV from the four different software’s in 166 patients. Furthermore, 
ventricular volumes from TRV (QBS, QUBE and 4D-MSPECT) were compared with 
those from BP-SPECT, the latter being the only method with a validation of 
ventricular volumes in literature.  
Results: Correlation for LVEF between PRV and TRV was good for all methods, 
being 0.81 for QBS, 0.79 for QUBE, 0.71 for 4D-MSPECT and 0.79 for BP-SPECT. 
Mean difference ± standard deviation (SD) was 3.16 ± 9.88, 10.72 ± 10.92, 3.43 ± 
11.79 and 2.91 ± 10.39 respectively. Correlation for RVEF between BP-SPECT and 
QUBE and QBS was poor, being 0.33 and 0.38 respectively.  
LV volumes calculated from QBS, QUBE and 4D-MSPECT correlated well with those 
from BP-SPECT (0.98, 0.90 and 0.98 respectively) with mean difference ± SD being 
7.31 ± 42.94, -22.09 ± 36.07, -40.55 ± 39.36 respectively, whereas RV volumes 
correlated worse between QBS and BP-SPECT and between QUBE and BP-SPECT 
(0.82 and 0.57 respectively). 
Conclusion: LVEF calculated from TRV correlates well with those from PRV but is 
not interchangeable with values from PRV. Volume calculations, for LV and RV, and 
RVEF need further validation before it can be used in clinical practice. 
 
Introduction 
 
Recently, different programs are being developed to process tomographic 
radionuclide ventriculography (TRV) 1-4. These programs are fast, provide left (LVV) 
and right ventricular volume (RVV) and ejection fractions (EF), but the validation of 
these parameters, mostly of the RV, remains scarce. We therefore wanted to 
compare LVEF calculated from planar radionuclide ventriculography (PRV) with 
values from TRV, calculated by four different programs, QBS 2, QUBE 3, 4D-MSPECT 
4 and BP-SPECT 1. For LVV and RVV calculations, we compared values from QBS, 
QUBE and 4D-MSPECT with those of BP-SPECT, the latter being the only algorithm 
with MRI-validation of volumetric parameters in literature 1,5. For the algorithm 4D-
MSPECT, only parameters of the LV were available. Furthermore, we wanted to 
compare LV and RV stroke volumes, calculated from TRV from QBS, QUBE and BP-
SPECT, as a method of validation of LV and RV volumetric parameters. 
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Materials and methods 
 
Data acquisition 
 
All images were acquired on two three-headed gamma camera’s (IRIX and Prism 
3000, Marconi-Philips, Cleveland, Ohio) equipped with low energy high-resolution 
collimators. PRV data were acquired over a 5 minute period, in 16 
electrocardiographic gated frames, 64 x 64 matrix, zoom 1.333 (pixel size 7 mm) 
and with a beat acceptance window at 20 % of the average R-R interval calculated 
just before the acquisition was started. The gamma camera was positioned in left 
anterior oblique projection in order to obtain the best “septal view”. Parameters of 
TRV acquisition were as follows: 360° step-and-shoot rotation, 40 stops per head, 
30 seconds per stop, 64 x 64 matrix, zoom 1.422 (pixel size 6.5 mm), and 16 time 
bins per R-R interval, with a beat acceptance window at 20% of the average R-R 
interval. Projection data were pre-filtered using a Butterworth filter (cutoff 
frequency: 0.5 cycles/cm; order: 5) and reconstructed by filtered backprojection 
using an x-plane ramp filter. Data were then reoriented into gated short axis 
tomograms. The resulting gated short axis data sets were then used as input for 
the four algorithms.  
From a database of 203 patients, who underwent PRV and TRV between 2001 and 
2004, 37 patients were excluded because the best septal view in left anterior 
oblique position was not reached during PRV, and these were all patients after 
heart transplantation. None of the patients had proven intracardiac or 
intrapulmonary shunting. 
From the remaining 166 patients (100 men, 66 women) clinical indications were 
pre-chemotherapy (55, 33%), post-chemotherapy (67, 40%), heart failure (8, 5%), 
acute myocardial infarction (7, 4%), pulmonary hypertension (3, 2%), congenital 
heart diseases (2, 1%) and other (24, 14%).  
 
Processing 
 
For the processing of the images, we used four software’s: QBS (Quantitative 
Bloodpool SPECT® software from Cedars-Sinai Medical Center, Los Angeles, USA), 
QUBE (Free University of Brussels, Brussels, Belgium), 4D-MSPECT (University of 
Michigan Medical Center in Ann Arbor, Michigan, USA) BP-SPECT (algorithms from 
Columbia University, New York, USA). 
For the validation of LVEF, we used PRV as the gold standard. PRV was processed 
with Multi-Gated Analysis, version march 2001, on an Odyssey workstation, Philips 
Medical Systems, The Netherlands. For the comparison of LVV and RVV, we 
compared data from QBS, QUBE and 4D-MSPECT with BP-SPECT, since this 
program is the only one available with validation of volumetric parameters. 
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Statistical Analysis 
 
Results were reported as mean values ± 1 standard deviation (SD). Correlations (r) 
between the different methods to calculate LVEF, LVV, RVEF and RVV were 
expressed as the Pearson coefficient. Variability about the regression line was 
expressed as the standard error of the estimate (SEE). Bland-Altman analysis of 
differences versus means of paired values was used to search for trends and 
systematic errors. Statistical significance was defined as p<0.05. Histograms and 
Box and whisker diagrams were used to show the distribution of the stroke volume 
index for the different techniques. 
 
Results 
 
Global results 
 
All gated short axis tomograms were processed on a pc, Pentium 4, 1.8 GHz, 512 
Mb RAM. Mean processing times were 105 sec, 18 sec, 19 sec and 15 sec for QBS, 
QUBE, 4D-MSPECT and BP-SPECT respectively. The automatic option for all 
programs was first performed, followed by a visual inspection of the delineation of 
both ventricles. This was done by reviewing the dynamic images, slices into short, 
horizontal long and vertical long axis images with the calculated outlines of both 
ventricles superimposed on it. 
QBS could successfully process the images automatically in 130 patients. From the 
other 36 patients, only 6 could be corrected by the manual option. The manual 
option for QBS is defining a ROI around the LV. After trying the automatic and 
manual option, in 3 patients there could be no satisfactory delineation of the LV 
and in 16 cases for the RV. For 11 patients, no result could be calculated at all. 
For QUBE, 114 patients were correctly processed by the automatic option. The 
manual intervention included masking, defining RV limit, condense number of gates 
or define septum and this revealed a good LV and RV delineation in 51 patients. 
Only in 1 patient, no result could be achieved for both ventricles. 
Seventy-one patients could be processed correctly with the automatic program of 
4D-MSPECT, in 85 patients, the atrioventricular border has to be adjusted manually, 
or a ROI around the LV had to be drawn. In 10 patients, no result could be 
calculated. No results for the RV were available. 
BP-SPECT could process the images completely automatic in 99 patients, whereas 
in the other 67 scans a satisfactory result could be achieved by drawing an end-
diastolic and an end-systolic ROI in the vertical long axis slice through the RV and 
LV together with one ROI through the short axis of both chambers. 
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Validation of LVEF 
 
Mean ± SD for LVEF from PRV and TRV are displayed in Table 1. Values of LVEF 
from all the methods to process TRV were significantly higher (P<0.001) compared 
to PRV. Furthermore, LVEF from QUBE was significantly higher (P<0.001) 
compared to the other methods of TRV. Regression and Bland-Altman analysis 
were performed for LVEF calculated with the four methods, compared to PRV 
(Figure 1). Correlation between PRV and TRV was good for all methods, being 0.81 
for QBS, 0.79 for QUBE, 0.71 for 4D-MSPECT and 0.79 for BP-SPECT. The standard 
error of the estimate (SEE) was smallest for QBS (9.86) and BP-SPECT (9.79), 
somewhat larger for QUBE (10.79) and for 4D-MSPECT (12.18). From Bland-Altman 
analysis, no significant trend was seen for all methods across the range of LVEF. 
 
Validation and compa ison of LVV, RVV and RVEF r
 
Mean ± SD for LVEDV, LVESV, RVEDV and RVESV from TRV are displayed in Table 
1. 
Regression and Bland-Altman analysis were performed for LVV calculated with QBS, 
QUBE and 4D-MSPECT, compared to LVV from BP-SPECT (Figure 2). LVV 
calculations from QBS, QUBE and 4D-MSPECT correlated well (0.98, 0.90 and 0.98) 
with values from BP-SPECT. All calculations of LVV, LVEDV and LVESV, showed the 
smallest values with 4D-MSPECT and largest with BP-SPECT. The values of LVEDV 
and LVESV from all the software’s differed significantly (P<0.001) with every other 
technique, except LVESV from QBS compared to BP-SPECT. In the Bland-Altman 
analysis, no significant trend was observed between LVV calculated by QBS and BP-
SPECT, but there was between QUBE and BP-SPECT and even more obvious 
between 4DM-SPECT and BP-SPECT, with a growing underestimation of LVV for 
QUBE and 4D-MSPECT for larger volumes. Furthermore, a lot of outliers were 
observed, especially between 4D-MSPECT and BP-SPECT and especially for larger 
volumes, and the variation of all methods depended strongly on the magnitude of 
measurements, by means that for large volumes difference between the two 
methods is often lying outside the 95% confidence interval (Figure 2). 
For RVV, correlation was slightly lower for QBS (0.82), but with an acceptable mean 
difference and confidence interval on Bland-Altman plot, and much lower for QUBE 
(0.57) compared to the values found by BP-SPECT (Figure 3). When considering 
RVEDV, no significant difference was found between QBS, QUBE and BP-SPECT, 
whereas for RVESV, only significant higher values were found for QUBE, compared 
to QBS and BP-SPECT, and not between values of QBS and BP-SPECT. 
For RVEF, significant differences were found between QBS and BP-SPECT and 
between QUBE and BP-SPECT and a poor correlation was found, 0.38 and 0.33 
respectively (Figure 4). 
Since the stroke volume (SV) is equal in LV and RV, proportion of stroke volumes 
(stroke volume index, SVI) has to be ideally 1. Histogram and Box and whisker 
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diagrams with the distribution of the SVI for the different techniques are shown in 
Figure 5. Mean SVI ± SD for BP-SPECT, QBS and QUBE were 1.01 ± 0.43, 0.99 ± 
0.38 and 1.11 ± 0.51 respectively. Half of the patients show a difference between 
LVSV and RVSV more then 40% for BP-SPECT, 39% for QBS and 54% for QUBE.  
 
 
Discussion 
 
QBS is a very straightforward program but with only very limited possible manual 
intervention. After automatic processing, the visual interpretation of the delineation 
of the ventricles is not optimal in 22% of the patients, this is mostly the case in the 
lateral wall of the left ventricle and in the inferior wall of both ventricles. Another 
error seen was the inclusion of atrial structures in the LV or RV. Only in 17% of 
these cases, the manual option (defining LV in short axis, horizontal long axis and 
vertical long axis) resulted in a satisfactory result, mostly for the LV. Nevertheless, 
this program is easy to use and the result page is visually attractive, with display of 
bull’s eye analysis of wall motion, similar to the well-known gated myocardial 
perfusion analysis software, QGS 6.   
QUBE is more validated 3,7-9 and is nowadays distributed by Segami coporation. The 
reconstruction software is directly linked to the software itself, with the obvious 
advantage of easily making corrections in realignment of the short axis images, 
zooming, masking and condensing 16 time frames into 8. The manual options gave 
satisfactory results in nearly all the cases, for LV as well as for RV. Additional 
results are presented like 3D phase analysis and RV fraction shortening, but these 
items remain unvalidated. 
4D-MSPECT is known for its analysis of gated myocardial perfusion 10, and it also 
includes a possibility to process TRV. At the moment of analysis, only the option of 
processing LV was available. The manual intervention is very fast and accurate in 
most of the cases, and the program is very flexible and open, which makes it 
possible to create own databases of normal patients and to export every parameter 
to a text-file to create an extensive and quantitative report. Wall motion is not only 
directly calculated in a predefined bull’s eye (3, 5, 9, 13, 17, 19 or 20 segment 
polar map), but can be scored as well as normal, mild hypokinesis, moderate 
hypokinesis, severe hypokinesis, akinesis or dyskinesis by predefined cut-offs. Only, 
there is a subjective impression that wall motion in the apex is relatively 
underestimated, compared to visual analysis of the images. Most of the scans 
needed manual intervention (51%), but this was easily done by adjusting the valve 
plane in end-diastolic and end-systolic position. The way these programs define the 
valve plane is a critical point and influences volume calculations extensively. The 
method used to detect the valve plane is not described by the manufacturers and 
can be completely automatically in one program and not adjustable (e.g. QBS), and 
visually less accurate and easily adjustable in another program (e.g. 4D-MSPECT). 
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BP-SPECT is the only software with validation of LVV and RVV 1,5 which is 
absolutely necessary for this kind of software. During processing, RV results are 
first calculated and when these are accepted, LV delineation is done. Drawing ROI’s 
in end-diastolic and end-systolic images for RV as well as LV, was successful in all 
clinical cases where the automatic program couldn’t define the ventricular outline 
properly. 
For the calculation of LVEF, all programs supply good results with correlation 
coefficients between 0.71 and 0.81. These values are lower than those mentioned 
in other publications about comparison of LVEF between PRV and TRV (Table 2.), 
although consistent with the finding that LVEF from TRV is higher compared to 
LVEF from PRV, probably because of atrial overlap with LV in PRV 11. A larger 
correlation is mainly found in papers with smaller patient groups, which makes it 
less representative for a large group of clinical patients or is found with a relative 
manual or semi-automatic technique, like the programs NuSMUGA 12 and TMUGA 
13. Like NuSMUGA, drawing LV ROI’s is all short axis slices in every time bin can 
derive accurate volume measurements when using an optimal cutoff, but you need 
an experienced user and it is clear that such a way of processing is very time-
consuming and will not be popular in clinical practice. Moreover, there is to our 
knowledge no possibility to process the RV with NuSMUGA in contrast to TMUGA, 
with even a comparison of LV and RV cardiac output measurements from TRV 
compared with the thermodilution method 13. The more the software is automatic 
(and reproducible), the more errors it produces and on the contrary, the more 
manual, the more time-consuming it is.  
For LVV calculations, the difference between the program with smallest values (4D-
MSPECT) and largest values (BP-SPECT) is almost double. The difference between 
4D-MSPECT and BP-SPECT in volume calculation was also shown in a four-chamber 
cardiac phantom experiment (submitted) whereas BP-SPECT overestimated LVV in 
another biventricular cardiac phantom experiment 14.  
The discussion about what technique gives the exact EF is inferior to the fact that 
TRV gives additional information, like each tomographic examination gives more 
information then a planar one. In this view it is also important to stress that, when 
describing a TRV, visual analysis of global and regional kinetic function of both 
ventricles should be included, even before delineation of ventricular volumes, 
without the influence of any (computerized) calculation. There were patients 
included in this study with a lower LVEF on PRV who showed a good contractility on 
TRV, and this is probably the cause of the “overestimation” of LVEF on TRV 
compared to PRV, but analysis of the gated reconstructed short axis slices showed 
a perfect contractility. 
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Limitations 
 
Using PRV as gold standard for LVEF is acceptable but validation of TRV, a 
technique that can produce volumes and EF of both ventricles, is better done by 
MRI, but this was not available in our database of patients.  
The relatively limited number of patients with impaired LV function (73% were 
cancer patients studies pre- and post chemotherapy) should also be stressed. 
 
Conclusion 
 
LVEF calculated from TRV with the four described methods correlate well with those 
from PRV and can be applied in clinical practice, although the values are not 
interchangeable with other techniques and even not within the same technique 
with other types of software.  
Volume calculations from TRV, especially from the RV, need further validation, 
mainly with other techniques, such as MRI, before they can be applied in clinical 
practice 
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Tables 
 
Abbreviations in the tables 
 
BP-SPECT: bloodpool SPECT 
LVEDV: left ventricle end-diastolic volume 
LVEF: left ventricle ejection fraction 
LVESV: left ventricle end-systolic volume 
M: manual method  
PRV: planar radionuclide ventriculography 
RVEDV: right ventricle end-diastolic volume 
RVEF: right ventricle ejection fraction 
RVESV: right ventricle end-systolic volume 
SD: standard deviation 
TRV: tomographic radionuclide ventriculography 
 
 
 
 53
AGREEMENT BETWEEN SOFTWARE ALGORITHMS IN BLOODPOOL SPECT 
Table 1 
 
Mean ± SD for PRV and TRV for all programs with paired T-test results for TRV compared to PRV. 
 
 
 PRV TRV 
  QBS QUBE 4D-MSPECT BP-SPECT 
LVEF 51.95±15.81 55.87±16.53* 62.87±17.40* 55.47±15.14* 54.86±16.01* 
LVEDV  129.55±81.43** 114.92±72.95** 88.10±63.16** 141.53±77.66 
LVESV  65.20±72.65 50.28±67.40** 44.12±55.74** 70.40±71.82 
RVEF  51.35±11.87** 47.47±13.51**  55.57±12.71 
RVEDV  133.96±40.92 141.81±55.39**  138.23±47.65 
RVESV  66.06±28.86 76.33±41.09**  62.85±32.44 
 
 
 
*: significant (p<0.05) difference compared to PRV 
**: significant (p<0.05) difference compared to BP-SPECT  
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Table 2 
 
Comparison of LVEF from PRV with TRV in literature 
 
 
 year N° pts Software Corr 
Linear 
Regression 
y = TRV; x = 
PRV 
Highest 
value SEE Ref. 
QBS 0.81 y = 0.86x + 10.51 TRV 9.1 
QUBE 0.79 y = 0.87x + 17.18 TRV 9.7 
4D-MSPECT 0.71 y = 0.67x + 20.66 TRV 11.5 
Our results 166 
BP-SPECT 0.79 y = 0.80x + 13.46 TRV 9.8 
 
QBS 0.81 y = 0.98 x + 5 PRV 10 
Nichols 2004 422 
BP-SPECT 0.83 y = 0.95 x + 7 TRV 9 
5 
NuSMUGA (M) 0.90  TRV  
Slart 2004 22 
NuSMUGA (A) 0.88  PRV  
15 
Wright 2003 50 QBS 0.80  -  16 
Ficaro 2002 56 4D-MSPECT 0.97 y = 1.06 x – 1.58 - - 4 
QBS 0.99 y = 0.92 x TRV 6.8 
TMUGA 0.98 y = 0.82 x TRV 8.1 Daou 2001 29 
M 0.98 y = 0.84 x TRV 8.4 
17 
Groch 2001 178 NuSMUGA 0.92 y = 1.04 x + 6.1 TRV 5.4 18 
Vanhove 2001 53 QUBE 0.78 y = 0.94 x + 6.33 TRV  (EF> 50%) 8.8 3 
Vanhove 2001 92 QUBE 0.82 y = 1.04 x – 4.75 TRV 8.8 
   QBS 0.80 y = 0.98 x + 4.42 PRV 9.4 
8 
Daou 2004 29 QBS 0.62  TRV  19 
Van 
Kriekinge 1999 89 QBS 0.89 
y = 1.01x + 2.00 TRV  2 
Chin 1997 18 M 0.96  TRV 6.7 20 
Bartlett 1996 23 Reprojection image 0.89 
y = 1.4 x - 8 TRV 8 11 
Mariano-
Goulart 1998 30 TMUGA 0.93 
y = 0.99 x + 4.17 TRV 5.9 13 
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Figures 
 
Figure Legends 
 
1. Figure 1 
a. Title: Linear regression and Bland-Altman analysis of left ventricular ejection fraction 
calculation of the four methods (QBS, QUBE, 4DM and BP-SPECT), compared with 
LVEF from PRV. 
b. First row: Results for QBS 
Second row: Results for QUBE 
Third row: Results for 4D-MSPECT 
Fourth row: Results for BP-SPECT 
 
2. Figure 2. 
a. Title: Linear regression and Bland-Altman analysis of left ventricular volumes (EDV 
and ESV) calculation of three methods (QBS, QUBE and 4DM), compared with left 
ventricular volumes from TRV (BP-SPECT) 
b. First row: Results for QBS 
Second row: Results for QUBE 
Third row: Results for 4D-MSPECT 
 
3. Figure 3. 
a. Title: Linear regression and Bland-Altman analysis of right ventricular volumes (EDV 
and ESV) calculation of two methods (QBS and QUBE), compared with right 
ventricular volumes from TRV (BP-SPECT). 
b. First row: Results for QBS 
Second row: Results for QUBE 
4. Figure 4 
a. Title: Linear regression and Bland-Altman analysis of right ventricular ejection 
fraction (RVEF) calculation of two methods (QBS and QUBE), compared with RVEF 
from TRV (BP-SPECT). 
b. First row: Results for QBS 
Second row: Results for QUBE 
5. Figure 5. 
a. Title: Histogram and Box and Whisker diagrams showing the distribution of the 
stroke volume index calculated by the three software’s. (Numbers above the Box 
and whisker diagrams being the lower whisker, lower hinge, median, upper hinge 
and upper whisker respectively) 
b. First row: Results for BP-SPECT 
Second row: Results for QBS 
Third row: Results for QUBE 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Chapter 2 
 
Human studies in patients with coronary artery disease 
and left ventricular dysfunction 
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2.1. Introduction 
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Abstract 
 
Coronary artery disease (CAD) is the leading cause of mortality in the Western 
world.  Multiple parameters have been investigated to predict prognosis in CAD 
patients.  The prognostic value of the assessment of LVEF in patients with CAD is 
well established.  More recently left ventricular (LV) volumes also showed a 
prognostic value.  The development of 99m-technetium (99mTc)-labelled myocardial 
perfusion tracers make it possible, due to the favourable imaging characteristics of 
99mTc (high-count density) to perform an electrocardiogram gated acquisition 
during routine myocardial perfusion imaging.  This enables us to assess LVEF and 
LV volumes during a myocardial perfusion scintigraphy.  This review aims to 
overview the possible prognostic abilities of LV volume assessment by gated cardiac 
SPET. 
 
Introduction 
 
Coronary artery disease (CAD) is the leading cause of mortality in the Western 
world.  Multiple prognostic parameters including left ventricular ejection fraction 
(LVEF) and left ventricular (LV) cardiac volumes have been introduced for 
management and follow-up of patients with CAD.  During the past decades 
radionuclide myocardial perfusion imaging using 201thallium (201Tl), first with planar 
and later with single photon emission tomography (SPET) images, has proven to be 
of high diagnostic and prognostic utility in predicting future cardiac events 1,2.  
Since the late eighties 99mTc-labelled perfusion tracers were developed and showed 
to be as valuable as 201Tl for perfusion imaging 3,4.  The favourable imaging 
characteristics (high count density) of 99mTc make it possible to perform an 
electrocardiogram-gated (ECG-gated) cardiac SPET during the acquisition of 
myocardial perfusion 5, which does not only improve the specificity for the detection 
of CAD 6, but also enables to assess LV functional parameters including LVEF and 
LV volumes 7,8.  This review aims to overview clinical relevant technical issues and 
the potential clinical and prognostic role of cardiac volume assessment with gated 
SPET in patients with CAD. 
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Evaluation of cardiac volumes:  
Overview of different techniques and technical issues 
 
A large and growing variety of methods is available to assess global LV function 
and volumes, including echocardiography, radionuclide techniques (radionuclide 
angiography (RNA) and myocardial gated SPET), magnetic resonance imaging 
(MRI) and cardiac angiography.  Each of these techniques is characterised by a 
variety of strengths and pitfalls.  The ideal technique for imaging global LV function 
should not only offer highly accurate and reproducible measurements of both LVEF 
and LV volumes but also be time and cost efficient, non-invasive and widely 
available.  Currently global LV function is, due to clinical circumstances, most 
commonly investigated by transthoracic echocardiography, which is widely 
available, readily accessible and inexpensive.  M-mode echocardiography and 2-
dimensional (2D) echocardiography, like all not truly 3-dimensional (3D) 
techniques, assume an ideal ellipsoidal geometry of the heart chambers to estimate 
cardiac volumes.  After myocardial infarction though, LV shape may be altered 
radically both due to infarct extension and the following remodelling process 9, 
which makes it impossible to make a good estimation of cardiac volumes and LVEF 
when assuming an ideal ellipsoid heart shape.  Transthoracic echocardiography is 
also limited by the need to obtain adequate acoustic windows, the fact that the 
measurements are operator dependent, sensitive to subjective analysis and have a 
poor reproducibility.  This poor reproducibility, operator dependency and 
assumption of a normal ellipsoid heart shape make echocardiography less attractive 
as follow-up tool of the remodelling heart.  Truly 3D techniques, like 3D 
echocardiography and 3D MRI but also gated SPET, do not require assumptions of 
a normal heart shape for accurate estimation of LV volumes.  All these tomographic 
methods have shown to be highly accurate and highly reproducible for the 
measurement of LV volumes and LVEF.  For example Chuang et al. compared 2D 
and 3D (volumetric) measurements, both with echocardiography and MRI in 35 
persons, 10 healthy volunteers and 25 patients with a dilated cardiomyopathy 10.  
The 3D techniques yielded very reproducible values and correlation between LV 
volumes and LVEF obtained by 3D echocardiography and 3D MRI was very high 
with narrow limits of agreement on Bland-Altman plot (2 standard deviations (SD) 
= mean ± 5% for LVEF) 11.  In contrast, agreement between LVEF and volumes 
estimated by the 2D methods and those obtained by the 3D techniques was poor 
although the mean values were comparable.  Agreement between both 2D 
techniques was very poor and so was reproducibility.  However because 3D MRI 
and 3D echocardiography require multiple cross-sectional views of the heart, they 
are very time consuming.  Thus even for these techniques biplane methods, 
requiring only two views and minimal data acquisition and analysis times, remain 
the method of choice in daily practice.  On the other hand, calculation of volumes 
by gated SPET is fully automated and easy to perform in daily clinical practice.  
Multiple automated methods have been developed to obtain functional information 
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out of a gated acquisition 5,7,8.  The most widespread method, Quantitative Gated 
Spect (QGS) is developed at Cedars Sinai, Los Angeles 5.  In this software package, 
different LV volumes during the cardiac cycle are measured by detecting the 
endocardium and valve planes in three dimensions, based on asymmetric Gaussian 
fitting of count profiles across the myocardium and identification of endo- and 
epicardial surfaces.  This provides series of contiguous short axis slices.  Cardiac 
volumes, most importantly LVESV and LVEDV, are measured by summing the area 
of the cavity in these slices following Simpson rule approximations.  In this method, 
volumes are calculated by summing LV surfaces of contiguous tomographic slices.  
Simpson rules approximations may be applied to data from any tomographic 
method for calculation of cardiac volumes and is used for volume estimation by all 
3D techniques.  Stroke volume (SV = LVEDV minus LVESV) and LVEF (LVEF = SV/ 
LVEDV) are calculated.  This makes 99mTc gated SPET an operator independent 
methodology with a very high reproducibility (the algorithm applied twice to the 
same dataset) 12,13 and repeatability 14-16.  Other advantages of gated SPET include 
the fact that function and quantitative perfusion are simultaneously acquired and 
displayed in the same image preventing misregistration errors, that acquisition is 
intrinsically tomographic and encompasses the entire ventricle in three-dimensional 
fashion and that acquired data are inherently digital, lending itself to quantitative 
analysis 17. 
 
Validation of global functional measurements by gated myocardial SPET 
versus other imaging techniques 
 
Multiple studies have been performed to validate measurements of LV function as 
estimated by gated cardiac SPET against other methods 5,7,8, 18-26.  LVEF estimated 
by automated gated cardiac SPET has a very good agreement with other 
techniques.  There is a good to excellent correlation in different comparatory 
patient studies with RNA, both equilibrium and first-pass, with r correlation values 
between 0.82 and 0.94 5,7,8,20,22,23.  Even in patients with large perfusion defects 
there is a very good correlation (r = 0.94) between LVEF measured by RNA and 
gated SPET 24.  This is explained because there is usually a minimal tracer uptake 
even in infarcted regions, which makes it possible to detect the endocardium 
accurately.  In contrast with these excellent correlations Vallejo et al. found only a 
fair correlation (r = 0.61) for LVEF between gated SPET (using QGS 5) and first-
pass RNA in 400 patients 25.  The fair correlation found by this group can be 
explained by the fact that cardiac studies were performed using both high dose 
(925-1110MBq) and low dose (444-555 MBq) injections.  Correlation between RNA 
and gated SPET was considerably better in studies with high dose injection versus 
those with low dose (r = 0.81 vs 0.61).  Also, automated border detection failed in 
9% of the studies due to high extra cardiac activity, leading to totally false border 
detection and volume measurements.  When they excluded studies where 
automatic border detection failed, overall correlation was better (r = 0.74).  
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Furthermore when comparing the means of LVEF estimated by gated SPET (using 8 
intervals) and RNA (using 16 intervals) they found that gated SPET underestimated 
LVEF by 4%.  This underestimation was already shown by Germano et al. who 
showed that LVEF assessed by gated SPET using 8 instead of 16 intervals 
underestimates LVEF by approximately 4% because of a smoothing of the time 
volume curve 5.  This underestimation is quite uniform over a wide range of values 
(LVEF range: 10-80%) and can be taken into account when interpreting LVEF 
values 5.  Vallejo et al. also found that LVEF obtained by gated SPET overestimates 
LVEF at high values compared with RNA 25.  This overestimation with gated SPET is 
found in small hearts and is caused by the relative limited spatial resolution of 
SPET, which makes endocardial border definition at end-systole difficult in small 
hearts 27.  This leads in small hearts to an underestimation of the LVESV and thus 
to an overestimation of the LVEF.  On the other hand correlation of LVEF 
determined by gated SPET and RNA tends to be higher for patients with a low LVEF 
24 and in this population assessment of LV functional parameters gives the most 
significant prognostic information.  Border detection and estimation of endocardial 
surface can also be affected by the amount of background activity, the injected 
dose and the presence of a perfusion defect 18,28.   
Bavelaar-Croon et al. compared LV parameters over a wide range of values (LVEF 
range: 10-80%) in 21 patients with gated SPET (16 intervals) and 3D-MRI, which is 
considered the reference standard for assessing global LV function due to its high 
resolution combined with a 3D technique 26.  Correlation between gated SPET and 
3D MRI was good for LVEF (r = 0.85), LVESV (r = 0.95) and LVEDV (r = 0.94).  
Bland-Altman plotting 11 did not reveal a significant over- or underestimation of 
LVEF.  There was a slight underestimation of volumes obtained by gated SPET in 
comparison with MRI, which is explained by the fact that calculation of LV volumes 
in cardiac MRI includes the outflow tract while this is never part of LV volumes 
acquired by gated SPET.  Because both the LV volumes, LVESV and LVEDV, are 
slightly underestimated by gated SPET this does not affect LVEF significantly.  
Other comparatory studies yielded also good correlations between gated SPET and 
MRI for the assessment LVEF (r = 0.82-0.93), LVESV (r = 0.87-0.99) and LVEDV (r 
= 0. 81-0.97) 8,29-34.  It must be mentioned that although there are many studies 
investigating correlation coefficients between measurements by gated SPET and 
other techniques, few studies used Bland-Altman plotting.  A significant correlation 
will always be found between two similar methods on repeated measurements in 
the same objects.  Bland-Altman plotting is necessary to investigate if the 
difference between measurements by two methods is small and to detect 
significant over- or underestimation of one technique opposed to another 11.   
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Are 201Tl and 99mTc ligands equivalent for volume assessment by 
myocardial gated SPET? 
 
99mTc ligands are ideal for gated acquisition during myocardial perfusion imaging 
due to their high count rate and image quality.  Recently Germano et al. reported 
the feasibility of a gated acquisition during myocardial perfusion SPET 35.  Few 
studies though investigated the accuracy of LVEF and LV volumes assessed by 201Tl 
myocardial gated SPET and study data are conflicting.  Tadamura et al. 34 found a 
good correlation between LVEF (r= 0.92), LVEDV (r= 0.85) and LVESV (r= 0.94) 
determined by 201Tl gated SPET versus 3D cardiac MR.  Bland-Altman analysis 
revealed no significant under- or overestimation.  Cardiac studies by this group 
were performed with high dose 201Tl (138 MBq) and a long acquisition time (16 
minutes).  There are however no validation studies for LVEF and LV volume 
measurements by low dose 201Tl gated SPET and it is not clear if results by a high 
dose protocol can be extrapolated towards lower doses (maximum dose is 74 MBq 
in the UK) and a reduced count rate.  Furthermore Lee et al. 36,37 found that 
repeatability of LVEF and LV volume measurements by 201Tl gated SPET (111 MBq) 
is not as good as that assessed by 99mTc gated SPET.  On the Bland-Altman plot 2 
SD is much larger in LVEF and LV volume measurements assessed by 201Tl versus 
99mTc MIBI (925 MBq) measurements (table 1).  This poorer repeatability makes 
that 201Tl gated SPET is less suited for the follow-up of changes in LV volumes and 
LVEF over time and also that it is less suited for prognostic purposes.  
 
 
Limits of normality 
 
To be useful as a diagnostic and follow-up tool, global functional information 
estimated by gated cardiac SPET requires determination of normative data.  Several 
institutes have proposed normal values for global LV functional measurements 
obtained by gated SPET at rest 38-41.  All these institutes performed gated SPET 
studies using 8 intervals.  Patients were included if they had a low pre-test 
likelihood of CAD 38-40 or no signs of CAD during the stress test (normal exercise 
capacity, normal ECG, no chest pain) in combination with a normal scan (perfusion 
and wall motion) 41.  A summary is given of normative functional data found by 
different groups (Table 2).  Data are expressed as mean ± SD.  Limits for normality 
can be calculated by mean ± 2 SD (Table 3).  Important differences are seen 
between sexes: women have a significantly higher mean resting LVEF and 
significantly lower LVESV and LVEDV 38-41.  LVEF and LVEDV are significantly related 
with body surface area (BSA), with a higher LVEDV and a lower LVEF when BSA 
increases 39.  There is no significant relationship observed between LVEF or cardiac 
volumes and age or heart rate 38,39. 
There are also no significant differences in normal limits of LVEF and LV volumes 
obtained after injection of 201Tl or 99mTc MIBI 41 or between measurements 
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acquired by different cameras (dual-headed Elscint CardiaL vs dual-headed ADAC 
CardioEpic vs triple-headed Picker Prism 3000 XP) 41.   Finally it has to be 
mentioned that gated SPET measurements of global LV function acquired post 
stress differ significantly from those acquired in resting condition (a higher LVEF 
and a smaller LVESV), so these data can not be used interchangeably 15, 38, 42. 
 
 
Prognostic studies 
 
One of the most powerful prognostic parameters in patients with CAD is LVEF.  This 
measure is not a pure measure of intrinsic myocardial contractility since its value 
depends on and is affected by other parameters, such as heart rate and cardiac 
loading conditions.  Despite this, LVEF has been found to be an extremely useful 
correlate of survival and thus a determinant of therapeutic decisions in a broad 
variety of cardiovascular disorders 43.  In particular both resting and exercise LVEF 
determined by radionuclide and other techniques is a major determinant of long-
term survival in patients with known CAD.  Since the development of RNA multiple 
studies have reported its important prognostic value as a non-invasive tool 44-47.  
However during the last decade short and long-term survival rates after acute MI 
improved markedly with the introduction of new reperfusion strategies 48.  This 
made it necessary to re-evaluate the prognostic value of LVEF estimated by RNA.  
Recently Shaw et al. 49 reported on 863 consecutive patients with known CAD, of 
which 68% had a prior history of MI.  All these patients underwent RNA, both at 
rest and during peak exercise, and cardiac catheterisation within 90 days.  LVEF 
determined at rest and during peak exercise provided information highly predictive 
of cardiac death (both p < 0.0001).  Patients with a resting LVEF ≤ 30% were 
stratified to exercise LVEF and had a hazard rate of 0.6 (for an exercise LVEF 31-
50%) and 3 (for an exercise LVEF ≤ 30%) deaths annually per 100 (p < 0.0001).  
In 759 patients with a resting LVEF > 30%, there were 2, 6 and 19 deaths annually 
per 100 patients for an exercise LVEF > 50%, 31-50% and ≤ 30% respectively.  
When all non-invasive information was considered, both resting and exercise LVEF 
contained significant predictive information for cardiac death (p < 0.0001).  In the 
prediction of cardiac death, rest and exercise RNA data also provided a significant 
incremental prognostic value above the anatomical information provided by cardiac 
catheterisation. 
Shigeyama et al. 50 retrospectively investigated 419 consecutive patients after acute 
MI who underwent an exercise RNA before hospital discharge.  Of these patients 
306 (73%) received reperfusion therapy, being either trombolytic therapy (201 
patients) or percutaneous transluminal coronary angioplasty (105 patients).  After a 
mean follow-up of 4.6 years, 24.1% of the patients had cardiac events as 
determined by recurrent myocardial infarction, unstable angina, congestive heart 
failure and ventricular tachycardia.  Death associated with cardiac events occurred 
in 4.3%.  Both peak exercise LVEF (p = 0.0140) and peak work load (p = 0.0018) 
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during exercise RNA were significantly lower in the group with cardiac events than 
in the group without events.  Regardless of the presence or absence of reperfusion 
therapy, a lower peak LVEF was associated with a decrease in event free survival 
rate.  Resting LVEF was also lower in the group with cardiac events, but this 
difference was not statistically significant (p = 0.2274).  These 2 recent studies 
indicate that even with current reperfusion strategies resting and peak stress LVEF 
can be used to predict future cardiac events in patients with CAD.  LVEF is by 
definition calculated out of the measured LVEDV and LVESV (conf. supra).  
Therefore is it possible that 2 patients with a comparable LVEF have totally 
different cardiac volumes.  Figure 1 shows the cumulative distribution of LVEDV at 
rest in 343 patients with CAD and LVEF  ≤ 40% (data from our Ghent gated SPECT 
database).  It can be noticed that a wide range of volumes can be found in patients 
with a reduced LVEF.  Even in patients with the same LVEF this wide range of 
volumes still exists.  This is illustrated in figure 2 where LVEDV and LVESV of 22 
patients with CAD and a calculated LVEF equal to 35 % are shown.  For example 
we show end diastolic short axis slices (figure 3) and summed perfusion bull ‘s eye 
images (figure 4) of 3 patients with a reduced LVEF of 29 % due to ischemic heart 
disease.  Although LVEF is equal in these 3 patients, they have totally different 
cardiac volumes, a different infarct extension and probably different prognostic 
prospectives.  The first patient has a small infarcted area and mildly dilated 
volumes; the second patient has a moderate infarcted area with larger cardiac 
volumes.  Patient 3 has much larger cardiac volumes, a large infarcted area and 
has inducible ventricular arrhythmias wherefore an implantable cardioverter 
defibrillator was indicated.   
Many studies have demonstrated the important prognostic value of dilated heart 
chambers, both for predicting cardiac events and cardiac death 51-67.  In 1987 
White et al. investigated the prognostic value of LVEF and cardiac volumes in 605 
male patients after first or recurrent MI 51.  LVEF and cardiac volumes in this study 
were obtained during catheterisation (X-ray left ventriculography).  Patients were 
followed for a mean period of 78 months (range 15-165 months) during which 
there were 101 cardiac deaths of which 70 % were sudden.  Patients who suffered 
from morbid events had larger LVEDV and LVESV than those who did not.  By 
multivariate analysis, LVESV (χ2 = 82.9) had a greater predictive value for survival 
than LVEDV (χ2 = 59.0) or LVEF (χ2 = 46.6).  Moreover, once the relationship 
between survival and LVESV had been fitted, there was no significant additional 
value neither for LVEDV or LVEF.  Similarly, Hamer et al. investigated a population 
of 193 patients after coronary artery bypass grafting (CABG) and followed them for 
a mean period of 133 months with a comparable result 52.  It has to be mentioned 
that the invasiveness of the procedure and the need of assumption of an ideal 
ellipsoidal geometry of heart chambers to estimate cardiac volumes by left 
ventriculography during catheterisation, makes this technique less suitable for 
follow-up of patients after cardiac events.   
 72
CLINICAL RELEVANCE OF MYOCARDIAL GATED SPECT IMAGING 
Although many studies investigated the prognostic value of different functional 
echocardiographic measurements in patients with CAD 53-56,58-60, 63,64,  and other 
echocardiographic studies investigated the evolution of LV volumes in CAD (with or 
without medical treatment) 68-70, very few investigated the prognostic meaning  of 
augmented LVESV and LVEDV.  Romano et al. 65 investigated LV volumes and LVEF 
by 2D echocardiography in 192 patients (143 males) after a first non-Q wave 
infarction and followed them for short-term outcome (events during the in-hospital 
period).  35 patients had hard events (death, reinfarction, recurrent angina or 
severe heart failure).  Indicators for poor short-term prognosis were higher age, 
worse wall motion and more frequent presentation with ST-depression, but also a 
significant lower LVEF (p < 0.01) and higher LVESV (p < 0.01).  There was a trend 
towards higher LVEDV volumes in patients with a poor prognosis, but this was not 
statistically significant.  It is however not clear if the assessment of global left 
ventricular function in this study had in incremental value above other parameters 
(age, ECG).  A large multi-centre prognostic study was performed by Nicolosi et al. 
(GISSI-3 trial) 66.  They investigated the prognostic value of global LV functional 
measurements by predischarge 2D echocardiography in a large population (8606 
patients).  Six hundred of these patients (=7%) had hard events (263 deaths and 
337 non-fatal late clinical congestive heart failures) during a 6 months follow-up 
period.  Patients were classified in quartiles according to the LV volumes and LVEF.  
They found that patients with LVEDV or LVESV in the highest quartile and LVEF in 
the lowest quartile had a significant augmented risk for death and non-fatal late ( p 
< 0.01 ).  
Cardiac MRI is, due to its high resolution and intrinsic 3D tomographic acquisition 
considered the ideal imaging modality for measuring cardiac volumes and changes 
in cardiac volumes over time.  However there are few studies investigating the 
prognostic value of these volumetric data.  Wu et al. 67 investigated a small group 
of 44 patients with cardiac MRI early after AMI (10 ± 6 days).  All but 2 received 
thrombolytics or direct angioplasty in the acute period.  In the early period after MI, 
patients with a microvascular obstruction had comparable LVEF and cardiac 
volumes compared to those without obstruction.  A second cardiac MRI study was 
performed 6 months after MI in a very small group of 17 patients, of whom 8 had 
microvascular obstruction in the early episode post infarction.  In patients with 
microvascular obstruction there was a significant rise in LVEDV (% rise 89.0 ± 77.8 
versus 9.8 ± 26.8%, p < .02) and LVESV (% rise 165 ± 199.6% versus 3.0 ± 19.8 
%, p < .04) compared with patients without obstruction.  For LVEF the difference 
was not statistically significant.  Sandstede et al. investigated in a short follow-up 
study only 12 patients after MI both with a resting and stress MRI.  Patients who 
had a lower LVESV and a higher LVEF on stress imaging compared to rest imaging 
had a greater improvement of global LV function after revascularisation than 
patients with a higher LVESV and a lower LVEF 71.  
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More recently Sharir et al. retrospectively investigated the prognostic value of post 
stress LVEF and volumes obtained by gated cardiac SPET in patients with known or 
suspected CAD 62.   A large population of 1680 patients underwent a rest 201Tl/ 
stress 99mTc MIBI myocardial gated SPET and were followed-up for a duration of 
569 ± 106 days.  They found that functional measurements obtained by 99mTc MIBI 
gated cardiac SPET after stress had an incremental prognostic value over perfusion 
data.  Most importantly LVEF and LVESV were strongly correlated with patient 
outcome.  Patients with a LVEF > 45% had mortality rates < 1% / year regardless 
of the severity of perfusion abnormalities, whereas patients with a LVEF < 45% had 
high mortality rates (9.2%/year) even with only mild to moderate perfusion 
abnormalities.  Similarly, a LVESV ≤ 70 ml was related to a low cardiac death rate 
(< 1.2%/y), whereas patients with a LVESV > 70 ml and only mild or moderate 
perfusion abnormalities had high death rates (8.2%/y), both regardless of the 
severity of perfusion abnormalities.  Most importantly, in patients with a LVEF < 
45%, a LVESV ≤ or > 70 ml distinguished between those at low and high risk for 
future cardiac events (cardiac death rate 1.7 %/y vs 7.9%/y).  Patients with LVEF 
> 45% had low cardiac event rates.  The grouping criteria of LVEF < 45% and 
LVESV > 70ml in this study were derived from ROC analysis afterwards.  
Multivariate analysis showed that in the prediction of total coronary events, 
perfusion variables and LVESV were independent and powerful predictors.  For the 
prediction of cardiac death and cardiac death or MI, post stress LVEF and LVESV 
were independent predictors and had an incremental value above perfusion data. 
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Future prospects 
 
Myocardial gated SPET is an accurate, operator independent and reproducible 
technique for the assessment of global LV function in patients with CAD.  Multiple 
centres around the world perform ECG gating during acquisition of myocardial SPET 
in daily practice.  These considerations make gated myocardial SPET a promising 
tool for the follow-up of changes in LV function and thus also for the assessment of 
prognostic information in patients with CAD.  There is however still a lot of work to 
do.  The retrospective analysis by Sharir et al. 62 is very promising but the 
prognostic value of LV functional parameters both at rest and after stress as 
assessed by gated SPET still has to be shown in large prospective studies.  Also, 
prognostic abilities of global function assessed by gated SPET must be investigated 
in high-risk populations of patients with CAD, such as the elderly and patients with 
heart failure due to CAD.  Furthermore it needs to be investigated whether patients 
with a significant decline of LVEF post stress in comparison to resting LVEF have a 
worse prognosis.  Finally a formal analysis of cost effectiveness of incorporating 
gated SPET perfusion imaging routinely into imaging protocols has not yet been 
reported.  However, because gated SPET software is fully automated and gating is 
already routinely acquired in order to improve specificity of perfusion imaging, the 
extra cost of gated SPET for assessing global LV function conjunction with standard 
perfusion imaging should be relative modest, in comparison with a separate 
assessment of ventricular function by other techniques. 
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Figures 
 
Figure 1 
 
Cumulative distribution of LVEDV at rest in 343 patients with CAD and LVEF ≤ 40%. 
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Data from the Ghent gated SPECT Database:  
2500 pts. (1850 males) with known or suspected CAD investigated by tetrofosmin gated SPECT 
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Figure 2 
 
Distribution of LVEDV and LVESV in 22 patients with CAD and a calculated LVEF of 35%. 
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Figure 3 
 
Short axis end diastolic images of 3 patients with a LVEF equal to 29% with totally different cardiac 
volumes. 
 
 
 
 
Figure 4 
 
Summed perfusion bull’s eye images of 3 patients with a LVEF equal to 29%. 
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Abstract 
 
Aim: To investigate the prognostic value of myocardial perfusion and function 
SPECT imaging in patients with coronary artery disease (CAD) and poor left 
ventricular (LV) function. 
Methods: We studied 261 patients (231 men, age 66±10 year) with CAD and a 
resting LV ejection fraction (LVEF) ≤40% assessed during myocardial gated SPECT. 
Perfusion defect extent was calculated using 4D-MSPECT® software (Michigan 
University). Ischemia scoring was performed visually. Considered end points were 
1) major cardiac events (MACE: cardiac death, non-fatal myocardial infarction or 
late revascularisation), 2) MACE or the need for hospitalisation due to heart failure 
(MACE-HF) and 3) cardiac death or non-fatal myocardial infarction. 
Results: During a median follow-up of 31 months, 52 patients (20%) died (35 
cardiac deaths), 50 (19%) developed a MACE and 69 (26%) a MACE-HF. In a 
clinical model, diabetes and angina status were the only predictors of MACE (χ2= 
19.3; p<.001). By multivariate analysis, post stress LVEF (χ2–gain of 6.4; p=.008) 
and presence of ischemia  (χ2–gain of 5.8; p=.018) were predictive of MACE. 
Similary, diabetes mellitus (χ2= 12.1; p<.001), post stress LVEF (χ2–gain of 5.5; 
p=.019) and presence of ischemia  (χ2–gain of 4.3; p=.044) were independent 
predictors of MACE-HF. Diabetes mellitus (χ2= 17.8; p< .001), presence of angina 
complaints (χ2–gain of 6.8; p=.028) and post stress LVEF (χ2–gain of 6.3; p=.008) 
were independent predictors of cardiac death or non-fatal myocardial infarction. 
Conclusions: In patients with impaired LV function and CAD, post stress LVEF is an 
independent predictor of future cardiac events.  
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Introduction 
 
Coronary artery disease (CAD) is the most common cause of heart failure in the 
Western world, accounting for 60-70 % of the cases 1. Incidence and prevalence of 
congestive heart failure due to CAD are increasing worldwide as a result of 
increasing life expectancy in general and the longer survival of patients with CAD in 
particular 2. Although rates of death from most cardiovascular diseases are stable 
or declining, mortality data from heart failure are less clear 3. Patients with CAD 
and impaired left ventricular (LV) function are at very high risk for cardiac death 
and future cardiac events 4.  
Myocardial ischemia assessed by nuclear myocardial perfusion imaging is a well-
known risk factor for future cardiac events in patients with known or suspected 
CAD 5-9. It is less clear whether ischemia is of prognostic importance in patients 
with depressed LV function. Revascularisation procedures have shown to improve 
prognosis in patients with CAD and a depressed LV function 10, but some studies 
suggest no prognostic value for the presence of ischemia in patients with a poor 
systolic LV function 11. The favourable imaging characteristics of 99m-Tc bound 
ligands make it possible to perform ECG gated cardiac Single Photon Emission 
Computed Tomography (SPECT) during the acquisition of myocardial perfusion 12, 
which not only improves the specificity for detection of CAD 13 but also permits the 
assessment of global LV functional parameters, including LV ejection fraction 
(LVEF) and LV volumes 14-15. The predictive value of global LV functional 
parameters can be assessed using different imaging modalities and have shown 
predictive value in patients with known or suspected CAD 16-21. The aim of this 
study was to investigate the predictive value of combined perfusion and function 
assessment during gated SPECT in patients with CAD and impaired LV function for 
prediction of future cardiac events.  
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Methods 
 
Study population 
 
All patients with ischemic heart disease and a resting LVEF ≤ 40 % determined by 
gated SPECT were prospectively evaluated (n=285) among 2168 consecutive 
patients referred for a 2 day stress-rest gated myocardial perfusion SPECT imaging 
in the period from October 1998 until December 2001. The diagnosis of ischemic 
heart disease was based on a history of myocardial infarction, percutaneous 
coronary intervention, coronary artery bypass grafting or angiographic significant 
CAD (at least one vessel with ≥ 75 % stenosis). Follow-up was achieved in 273 
patients (95 %). Twelve patients were excluded because they had an early 
revascularisation procedure within 3 months following the myocardial SPECT 8. 
Therefore 261 patients (231 males) formed the study population. 
 
Stress testing 
 
Bicycle stress testing was used in patients able to perform maximal physical stress 
(n= 130, 50%). Each subject underwent maximal exercise testing on a computer-
driven bicycle ergometer (Ergoselect, Ergoline GmbH, Bitz, Germany) using a ramp 
protocol starting at 50 Watts with gradual increase of 25 or 10 Watts according to 
the general condition of the patient. A standard 12-lead ECG was continuously 
recorded and the heart rate was followed.  Blood pressure was measured by means 
of a mercury sphygmomanometer at each stage and at the peak of exercise. 
Subjects were exercised to their self-determined maximal capacity or until the 
physician stopped the test because of significant symptoms, such as chest pain or 
dizziness, potential dangerous arrhythmias or ST-segment deviations, or marked 
systolic hypotension or hypertension.  
When a patient was not able to perform maximal bicycle stress (n= 27, 10%), an 
additional intravenous infusion of dipyridamole was given (infusion over a 4 minute 
period, 0.142 mg/kg/min).  
In patients who were not able to perform bicycle stress at all (n= 104, 40%), only 
dipyridamole was given (infusion over a 4 minute period, 0.142 mg/kg/min). 
Patients were informed not to consume caffeine-containing products for 24 hours 
before testing. At peak stress 900 MegaBecquerel Technetium-99m tetrofosmin was 
injected. 
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Gated SPECT acquisition and reconstruction 
 
Stress and rest studies were performed in a 2-day protocol as described previously 
22. In both stress and rest studies, 900 MegaBecquerel (25 milliCurie) of 
technetium-99m tetrofosmin was injected intravenously. Imaging was started 
between 30-60 minutes after injection in the resting state and 15-30 minutes after 
injection at peak stress. A gated SPECT acquisition was performed over 360° in 
step-and-shoot mode (120 sectors of 3°, 30 seconds/ step, matrix size 64 x64) 
using a triple-headed camera (Picker Prism 3000, Marconi, Philips, Cleveland, Ohio) 
equipped with low energy all-purpose collimators. Acquisitions were gated for 8 
frames per cardiac cycle. There was a 20 % acceptance window around the 140 
keV photon peak. Attenuation correction, background subtraction and beat 
rejection were not performed. The raw gated SPECT data were ungated and 
reconstructed using filtered back projection (ramp filter) and post-filtered using a 
low pass filter (order 5, cut-off frequency .21). The left ventricle was reoriented 
manually to obtain short axis gated and ungated images. The gated images were 
processed using Quantified Gated SPECT software (QGS®, Cedars-Sinai, Los 
Angeles, CA, USA) to obtain resting and post stress LVEF and LV volumes. 
 
Scoring of the perfusion images 
 
The ungated short axis images were used for semi-quantitative determination of 
myocardial defect extent on stress and rest myocardial perfusion images using 4D-
MSPECT® software (University of Michigan, Ann Arbor, Mi, USA) by comparison 
with a gender specific normal perfusion database generated at our institution. 
These stress and rest normal database files were made out of patients with a low 
cardiac risk (< 5 %) 23. Ischemia scoring was made visually by comparing short 
axis, vertical and horizontal long axis on stress and rest images. 
 
Clinical data and follow-up 
 
Demographic data at study entrance were collected by reviewing hospital records. 
Hypertension was defined as a blood pressure ≥ 140 / 90 mmHg or treatment with 
antihypertensive medication. Diabetes mellitus was defined as a fasting blood 
glucose level > 140 mg/ dl or the need for insulin or oral antidiabetic agents. 
Follow-up data were collected in 2003. One author (ODW) contacted patients’ 
general practitioners and reviewed hospital records. The author was blinded to 
scanning results at the time of follow-up. A standard questionnaire was used for 
follow-up interviews. The following cardiac events were taken into account: non-
fatal acute myocardial infarction, percutaneous coronary intervention, coronary 
artery bypass grafting, the need for hospitalisation because of heart failure, death 
and cause of death. Cardiac death was defined as death caused by acute 
myocardial infarction, refractory congestive heart failure, clinically important cardiac 
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arrhythmias and sudden death without another explanation. The need for cardiac 
transplantation (n = 2) was also considered as cardiac death. Myocardial infarction 
was defined according to the Joint European Society of Cardiology/ American 
College of Cardiology Committee criteria 24. Patients who died from non-cardiac 
causes were censored on the day of their death. The time of the last patient 
contact was used to determine the end of the follow-up period in patients without 
events. Follow-up was limited to 36 months.   
Three combined cardiac end points were defined in advance and used for further 
analysis: 
1) MACE: cardiac death, non-fatal myocardial infarction, percutaneous coronary 
intervention or coronary artery bypass grafting.  
2) MACE-HF: MACE or the need for hospitalisation due to heart failure. 
3) Cardiac death or non-fatal myocardial infarction. 
 
If a patient died from a cardiac cause, only cardiac death was considered. If there 
were 2 or more non-fatal events in one patient, only the event that came first in 
time was considered. 
 
The study was approved by the local Ethics Committee of the Ghent University 
Hospital.  
 
Statistical analysis 
 
Statistical analyses were performed using SPSS 11.0.1 statistical software (SPSS 
Inc., Chicago, USA). Data are shown as median (25th – 75th percentile) or number 
(%). Non-parametric Mann-Whitney U testing or Chi-square testing was used to 
assess differences in clinical and SPECT variables between patients with and 
without events. Kruskal-Wallis testing was used to investigate trends in event rates 
between groups. Cumulative event free survival rates as a function over time were 
obtained by the Kaplan-Meier method. Differences in survival were analysed by log-
rank testing. Clinical parameters significant by univariate analysis were forced into 
a stepwise multivariate Cox proportional hazards regression model to identify 
SPECT variables (functional parameters at rest and post stress, stress and rest 
defect extent and presence of reversibility) predicting cardiac events independently 
and incrementally above clinical parameters. Significance was set at < .05. 
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Results 
 
Clinical cha acteristics of patients with and without events r
 
Patients’ characteristics are summarized in table 1. Median age was 67 years. Of 
the 261 patients 231 (89 %) were male. At the time of myocardial SPECT imaging 
174 patients (67 %) had a history of myocardial infarction, 45 patients (17 %) a 
history of percutaneous coronary intervention and 58 patients (22 %) previously 
underwent coronary artery bypass grafting. At the start of the follow-up period, 133 
patients (51 %) were taking beta-blockers and 188 (72 %) angiotensin-converting 
enzyme inhibitors or angiotensin-II receptor blockers as medical treatment (see 
further table 1).  
 
Gated SPECT variables in patients with and without events 
 
During a median follow-up of 31 months (interquartile range 21-36 months), 52 
patients (20 %) died of which 35 deaths (13 % of the total population) were 
considered cardiac. This means that 67 % of the death causes in this population 
were cardiac. There were 50 patients (19 %) who developed a MACE and 69 (26 
%) a MACE-HF. In the whole population, the annual event rate was 8.4 % for 
MACE and 12.1 % for MACE-HF. Patients who developed a MACE during follow-up 
were more likely to be diabetic and to have angina complaints (table 1). When 
considering MACE-HF, the presence of diabetes mellitus was the only significant 
clinical variable in the univariate analysis (p = < .001). Table 2 shows the results of 
the gated SPECT variables in all patients and in patients with and without MACE. 
Patients who developed a MACE during follow-up had a lower post stress LVEF and 
more frequent presence of ischemia on perfusion imaging. Patients with a MACE-HF 
similarly showed more presence of ischemia (45% versus 30%; p= .022) and a 
lower post stress LVEF (p= .027) when compared to patients without a MACE-HF. 
Cardiac event rates were significantly higher in patients with ischemia on perfusion 
imaging (table 3). Kaplan-Meier survival analysis and log-rank testing showed that 
patients had significantly more MACE (figure 1) (p= .003) and MACE-HF (figure 2) 
(p= .028) during the follow-up period when they had ischemic myocardium 
visualised on myocardial perfusion imaging. Similary, Kaplan-Meier curves showed a 
significant shorter event free survival time for MACE (figure 3) (p= .020) and 
MACE-HF (figure 4) (p= .044) when patients had a lower post stress LVEF. 
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Multivariate predictors of cardiac events 
 
With diabetes and the angina status as the major clinical variables included into the 
stepwise multivariate Cox regression model for MACE, adding of post stress LVEF 
provided a Chi-square gain of 6.4 (p= 0.008). When the ischemia detection was 
added to this model, there was an additional Chi-square gain of 5.8 (p = 0.018)  
(figure 5).  
In the clinical model of MACE-HF, only diabetes was significant and was forced in 
the multivariate analysis. Adding of post stress LVEF provided a Chi-square gain of 
5.5 (p= .019) and ischemia detection on perfusion imaging an additive Chi-square 
gain of 4.3 (p= .044) in this model (figure 5). 
 
Uni- and multivariate predictors of cardiac death or non-fatal myocardial infarction 
 
Univariate predictors of cardiac death or non-fatal myocardial infarction were 
diabetes mellitus (p < .001), presence of angina complaints (p = .005), a higher 
NYHA classification (p = .026), a lower resting and post stress LVEF (p= .013 and 
.017 respectively). Diabetes mellitus (Chi-square = 17.8; p< .001) and presence of 
angina complaints (Chi-square gain of 6.8; p= .028) were independent clinical 
predictors in the Cox regression analysis. Adding of post stress LVEF to the model 
provided an additive Chi-square gain of 6.3 (p = .008). Considering this end point, 
there was no significant predictive value for ischemia detection (p= .112). 
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Discussion 
 
The results of this study indicate that the combined assessment of function and 
perfusion using technetium-99m tetrofosmin gated SPECT provide significant and 
independent predictive information regarding the subsequent risk of major cardiac 
events in patients with CAD and systolic LV dysfunction.  
 
Prognostic value of myocardial perfusion assessment 
 
Multiple studies investigated the prognostic value of myocardial perfusion imaging 
in subjects with known or suspected CAD for predicting cardiac events and 
mortality 7,9,25-29. However, these prognostic data were all collected in patient 
populations with known or suspected CAD and only few data are available 
regarding the prognostic value of myocardial perfusion imaging in patients with 
impaired LV function and known CAD. The risk for subsequent cardiac events is 
much higher in this population than in the generally investigated populations 30. 
Therefore, results and risk factors found in other populations may not be 
extrapolated 31.  
Data on the prognostic value of myocardial perfusion imaging in patients with CAD 
and LV dysfunction are scarce. In concordance with our data, Miller et al. found a 
higher revascularisation rate, but no difference in survival between patients with 
large ischemic defects versus patients with large fixed defects in 214 patients with 
a LVEF <45 % 32.  In 156 patients with CAD and a LVEF < 30 %, Sharir et al. also 
did not find a difference in mortality in patients with fixed versus reversible defects 
11. As expected, ischemia was frequently detected in our study population. Thirty-
four percent had ischemia on myocardial perfusion imaging. Patients with ischemia 
were at increased risk for MACE and MACE-HF but not for cardiac death or non-
fatal myocardial infarction.   
 
Prognostic value of LV functional parameters 
 
One of the most powerful prognostic parameters in patients with CAD is the LVEF. 
Multiple studies have demonstrated the important prognostic value of this 
parameter assessed using planar radionuclide angiography 19-21 or using other 
imaging modalities 16-18 in patients with known or suspected CAD. Our data 
demonstrated that even in this population in which all patients had a depressed 
LVEF and the spreading of LVEF values was narrow, post stress LVEF was highly 
predictive for future cardiac events. 
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Importance of combined perfusion and function assessment in patients with CAD 
and poor LV function using gated SPECT 
 
The addition of LV ventricular functional data to myocardial perfusion imaging has 
shown benefit in diagnostic settings by increasing specificity and decreasing the 
number of borderline interpretations 13,33,34. Another potential diagnostic use is in 
identifying patients with multivessel disease who might be otherwise missed by 
myocardial perfusion imaging 35. 
There are however limited data on the prognostic value of LVEF as assessed by 
gated SPECT in patients with impaired LV function. As part of a larger study, Sharir 
et al. 36 investigated a subgroup of 277 patients with suspected CAD and a LVEF < 
45% using gated SPECT and followed these during 19 ± 5 months. They concluded 
that it is possible to further risk stratify patients these patients upon a post stress 
LV end systolic volume with 70 ml as cut-off value. Although the size of our study 
group was comparable and our follow-up was even longer, we did not find an 
important predictive value for cardiac volumes in our study. Only 20 patients (7.8 
%) in our population had a post stress LV end systolic volume < 70 ml and these 
patients had no significant lower mortality than those with a LV end systolic volume 
≥ 70 ml. In our study group, there was a trend towards a higher resting (p= .084) 
and post stress (p= .0100) LV end systolic volume in patients with a subsequent 
hard event (cardiac death or non-fatal myocardial infarction). However, once the 
post stress LVEF was added to the model, there was no further predictive value for 
LV volumes. 
Since myocardial perfusion imaging is used in daily clinical practice for diagnosis 
and follow-up of patients with CAD and LV dysfunction and ECG gating during the 
acquisition of myocardial SPECT can be easily performed in daily practice, gated 
SPECT could be an ideal tool for risk stratification in this patient population. 
 
 
Study limitations 
 
Because only 130 (50 %) of the 261 patients were able to perform maximal bicycle 
exercise stress, a possible incremental prognostic value of nuclear imaging 
variables above parameters obtained during bicycle stress (stress 
electrocardiography changes, maximum workload or blood pressure change) could 
not be assessed. 
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Conclusions 
 
This study showed the significant incremental power of nuclear imaging data over 
clinical data in predicting cardiac events in patients with a depressed systolic LV 
function due to CAD. A lower post stress LVEF is an independent predictor of future 
cardiac events in patients with CAD and impaired systolic LV function. 
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Tables 
 
Abbreviations in the tables 
 
ACE-I: Angiotensin-Converting Enzyme Inhibitors 
AT-IIA: Angiotensin-II antagonists 
BMI: body mass index 
CABG: coronary artery bypass grafting 
ECG: electrocardiogram 
ICD: implantable cardioverter defibrillator 
LVEDV: left ventricular end diastolic volume 
LVEF: left ventricular ejection fraction 
LVESV: left ventricular end systolic volume 
MACE: major cardiac event 
MACE-HF: major cardiac event or hospitalisation due to heart failure. 
MI: myocardial infarction 
n: number 
NYHA: New York Heart Association classification 
PCI: percutaneous coronary intervention  
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Table 1 
 
Clinical characteristics of all patients and comparison between patients with and without MACE. 
 
Variables 
All patients 
(n = 261) 
Patients 
without MACE 
(n =  211) 
Patients 
with MACE 
(n = 50) 
P 
value 
Demographics     
Age (year) 67 (59-73) 67 (59-73) 70 (58-75) .253 
Gender (males) 231 (89%) 188 (89%) 43 (86%) .537 
BMI (kg/m2) 26.2 (23.6-28.7) 26.0 (23.5-28.7) 26.6 (23.9-28.2) .887 
     
Functional status     
NYHA I-II 242 (93%) 198 (94%) 44 (88%) .144 
NYHA III-IV 19 (7%) 13 (6%) 6 (12%) .144 
Angina 29 (11%) 18 (9%) 11 (23%) .005 
     
Risk factors     
Hypertension 121 (46%) 98 (46%) 23 (46%) .887 
Diabetes mellitus 58 (22%) 38 (18%) 20 (40%) .001 
Serum cholesterol (mg/dl) 198 (173-230) 198 (173-227) 197 (175-252) .409 
     
Cardiac history     
History of MI 174 (67%) 142 (67%) 32 (64%) .657 
History of PCI 45 (17%) 37 (18%) 8 (16%) .796 
History of CABG 58 (22%) 51 (24%) 7 (14%) .121 
     
ECG     
Resting heart rate ( beats /’) 69 (60-78) 68 (60-77) 70 (60-79) .586 
Atrial fibrillation/ flutter 19 (7%) 15 (7%) 4 (8%) .828 
ICD implanted 63 (24%) 54 (26%) 9 (18%) .253 
     
Medication     
Aspirin 166 (64%) 133 (63%) 33 (66%) .671 
Aspirin or coumarin 200 (77%) 163 (77%) 37 (74%° .620 
B-blockers 133 (51%) 109 (52%) 24 (48%) .645 
ACE-I or AT-IIA 187 (72%) 152 (72%) 35 (70%) .780 
ACE-I or AT-IIA or B-blockers 215 (82%) 175 (83%) 40 (80%) .744 
Diuretics 85 (33%) 69 (33%) 16 (32%) .931 
Spironolactone 9 (3%) 6 (3%) 3 (6%) .271 
Digitalis 43 (16%) 33 (16%) 10 (20%) .450 
Amiodarone 23 (9%) 19 (9%) 4 (8%) .840 
 
Data are presented as median (25th-75th percentile) or number (%) 
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Table 2 
 
Gated SPECT variables of all patients and comparison between patients with and without major 
cardiac events. 
 
 
 
 All patients (n = 261) 
Patients without 
MACE 
(n =211) 
Patients with 
MACE 
(n = 50) 
P value 
Left ventricular function     
Resting LVEF (%) 29 (23-35) 30 (24-36) 27 (22-34) .054 
Resting LVEDV (ml) 191 (147-241) 188 (147-238) 199 (153-256) .217 
Resting LVESV (ml) 132 (98-179) 128 (97-174) 144 (101-202) .123 
Post stress LVEF (%) 31 (24-37) 31 (25-38) 27 (21-33) .014 
Post stress LVEDV (ml) 193 (152-243) 191 (151-239) 200 (163-251) .258 
Post stress LVESV (ml) 133 (94-177) 130 (94-176) 146 (109-193) .098 
Perfusion      
Defect extent stress (%) 38 (22-50) 36 (22-49) 39 (22-55) .349 
Defect extent rest (%) 30 (17-46) 30 (17-46) 29 (16-45) .854 
Presence of ischemia (%) 88 (34%) 62 (29%) 26 (52%) .002 
 
 
Data are presented as median  (25th – 75th percentile) or number (%) 
 
 
Table 3 
 
Annual cardiac event rate according to the presence of ischemia on myocardial perfusion imaging. 
 
 
 MACE MACE-HF  
No ischemia (n = 173) 6.0 % 9.8 % 
Ischemia (n = 88) 13.5 % 16.7 % 
Overall p p = .003 p = .022 
 
 
Annual cardiac event rate= number events/ person years  
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Figures 
 
Abbreviations in the figures 
 
LVEF: left ventricular ejection fraction 
MACE: major cardiac event  
MACE-HF: major cardiac event or hospitalisation for heart failure  
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Figure 1 
 
Kaplan-Meier curves for MACE free survival according to the presence or absence of ischemia 
detected by myocardial perfusion imaging 
 
 
 
 
 
Figure 2 
 
Kaplan-Meier curves for MACE-HF free survival according to the presence or absence of ischemia 
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Figure 3 
 
Kaplan-Meier curves for MACE free survival according to the post stress LVEF  
(in tertiles) 
 
 
 
 
Figure 4 
 
Kaplan-Meier curves for MACE-HF free survival according to the post stress LVEF (in tertiles) 
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Figure 5 
 
Chi-square found by stepwise multivariate analysis for the clinical model and when post stress LVEF 
and the amount of ischemic myocardium is added to the model. 
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Abstract 
 
Background: Patients with coronary artery disease (CAD), a QRS duration ≥120 ms 
and left ventricular ejection fraction (LVEF) ≤30% are potential candidates for 
cardiac resynchronisation therapy (CRT). Our aim was to investigate the 
relationship between QRS duration, left ventricular volumes and prevalence of 
nonviable tissue in this patient population. 
Methods: We studied 132 patients (118 men, age 68±5 years) with CAD and LVEF 
≤30% (mean LVEF 24±6 %).  LV volumes and myocardial viability were 
determined by gated myocardial perfusion imaging. 
Results: A QRS duration ≥ 120 ms was present in 91 patients (69%).  Although 
there were no differences in LVEF, patients with longer QRS durations had 
significant larger end-diastolic and end-systolic volumes (p<0.01). Substantial non-
viable tissue in the inferior or lateral wall was present in 29% of patients with a 
QRS duration ≥120 ms versus 7% of those with a QRS duration <120 ms (p<0.01).  
Conclusions: An increased QRS duration is associated with more advanced 
remodeling in patients with CAD and poor LV function. Almost one third of these 
patients with a prolonged QRS duration have no viable tissue in the inferolateral 
wall, an area that is usually stimulated with CRT.  
 
Background 
 
Cardiac resynchronisation therapy (CRT) is considered as a potential therapeutic 
option in patients with heart failure, reduced left ventricular ejection fraction (LVEF) 
and an increased QRS duration. Although functional improvements and effects on 
morbidity and mortality have been reported, up to 30 % of CRT patients do not 
respond to this therapy and this percentage could be even higher in patients with 
underlying coronary artery disease (CAD) 1-3. One of the reasons could be the 
presence of non-viable tissue in the inferolateral wall which is usually paced when 
the LV lead is placed transvenously via the coronary sinus.  
 
Aims 
 
Our study aims were to assess the relationship between QRS duration on the 
surface ECG, left ventricular volumes and the prevalence of nonviable tissue in 
patients with CAD and poor LV function. 
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Methods 
 
We studied 132 consecutive patients with CAD and a resting LVEF ≤ 30 %. The 
diagnosis of CAD was based on a history of myocardial infarction, coronary 
revascularisation or angiographic significant CAD (at least one vessel with ≥ 75 % 
stenosis). All patients were studied more than 3 months after myocardial infarction 
or revascularization and patients with ventricular pacing on the resting ECG were 
excluded. QRS duration was measured on a 12-lead surface ECG, at a speed of 25 
mm/s, from the resting ECG. 
All patients underwent a resting gated myocardial perfusion SPECT study using 
technetium-99m tetrofosmin as described previously 4. Quantified Gated SPECT 
software (QGS®, Cedars-Sinai, Los Angeles, CA, USA) was used to obtain resting LV 
ejection fraction and volumes. For viability scoring, the myocardium was divided in 
5 regions, anterior wall, lateral wall, inferior wall, septal wall and apex. The 
anterior, lateral, inferior and septal wall were subdivided in 3 regions (apical, mid 
and basal region), the apex was subdivided in 2 regions 5. A myocardial wall was 
considered to contain substantial non-viable tissue if none of the segments had a 
mean myocardial uptake higher than 55% of the maximum uptake in the 
myocardium on the resting perfusion images 6. 
Statistical analyses were performed using SPSS 11.0.1 statistical software (SPSS 
Inc., Chicago, USA). Spearman rank correlations, Mann-Whitney U and Kruskall-
Wallis testing were used to investigate relations between QRS duration and LV 
volumes and prevalences of nonviable according to QRS duration. 
The study was approved by the local Ethics Committee of the Ghent University 
Hospital. 
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Results 
 
Mean age of the 132 patients was 68±5 years and mean LVEF was 24±6 %. 
Previous myocardial infarction was present in 86 (65%) and previous coronary 
revascularization in 63 (48%) patients. According to the SPECT findings, the 
anterior wall was infarcted in 21 (16 %), the septal wall in 19 (14 %) and the 
inferolateral in 73 (55 %) patients. Patients were treated with ACE-inhibitors or AT-
2 receptor blockers (n=98, 74%), beta-blockers (n=59, 45%) and diuretics (n=48, 
36%). Mean QRS duration was 131±32 ms and a QRS duration ≥ 120 ms was 
present in 91 patients (69%). For the whole group QRS duration correlated 
significantly with LV enddiastolic volumes (r=0.31, p<0.001) and LV endsystolic 
volumes (r=0.30, p<0.001). As compared to patients with small QRS, patients with 
QRS duration > 120 ms had significantly higher LV enddiastolic volumes (248±77 
vs 205±73 ml, p<0.01) and LV endsystolic volumes (193±68 vs 159±60 ml, 
p<0.01). Figure 1 shows the mean LV enddiastolic and endsystolic volumes 
according to four classes of QRS duration. No significant relation was found 
between LVEF and QRS duration. 
The inferior or lateral wall was nonviable in 26 patients with a QRS duration ≥ 120 
ms (29%). This frequency was significantly higher than in patients with QRS 
duration < 120 ms (29% vs 7%, p<0.01). Prevalences of nonviable tissue in 
different regions for patients with QRS < 120 ms and QRS ≥ 120 ms are shown in 
figure 2. 
 
Conclusion 
 
Our results indicate that a prolonged QRS duration (≥120 ms) is frequent in 
patients with CAD and LVEF ≤ 30% with a prevalence of almost 70%. Similar to 
previous studies in patients with idiopathic dilated cardiomyopathy 7-9, this increase 
in QRS duration is clearly related to an increase in LV enddiastolic and endsystolic 
volumes, indicating more advanced remodeling in these patients. More importantly, 
absence of viable tissue in the inferolateral wall in CAD patients with poor LV 
function is frequent, with a prevalence of 29% when QRS duration is increased as 
compared to only 7% when QRS duration is < 120 ms. This implicates that almost 
30% of potential candidates for CRT with CAD have non-viable tissue in the 
inferolateral wall. Since non-viable tissue is electromechanically non-functional 10 
placement of the lead in the inferolateral region could lead to ineffective pacing in 
these patients 11. This could therefore be one of the explanations why CRT is 
ineffective in a substantial number of patients with CAD. Further studies are 
however needed to determine whether viability assessment can help in the 
selection of candidates for CRT and in the determination of optimal lead 
localisation. 
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Figures 
 
Figure 1 
 
Relationship between QRS duration and left ventricular volumes.  A significant 
increase in LV endiastolic (EDV) and endsystolic (ESV) volumes is noted according 
to QRS duration. 
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Figure 2 
 
Prevalence of nonviable tissue in different myocardial regions in patients with QRS 
duration < 120 ms and patients with QRS duration ≥ 120 ms.  A significantly higher 
prevalence of nonviable tissue in the inferolateral wall is noted in patients with QRS 
duration ≥ 120 ms. 
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Abstract 
 
Coronary artery disease (CAD) is the major cause of morbidity and mortality in the 
elderly population. Due to aging of the population and better medical, 
interventional and surgical treatment of patients with CAD, more and more elderly 
patients are referred to the cardiology department for diagnostic work-up. Stress 
testing in combination with myocardial perfusion imaging (MPI) is routinely used in 
elderly patients, a population where the diagnosis of significant CAD is often 
challenging because of atypical symptomatology. Since the introduction of 
technetium-99m ligands for MPI, it is possible to perform ECG gated perfusion 
imaging. This does not only improve the specificity of the test for CAD detection, it 
also enables the simultaneous assessment of left ventricular functional parameters. 
This article briefly overviews possible stress modalities, diagnostic accuracy and 
prognostic value of MPI in elderly patients. 
 
I. Introduction 
 
Coronary artery disease (CAD) is the major cause of morbidity and mortality in the 
elderly population 1-4. Due to aging of the population and better medical, 
interventional and surgical treatment of patients with CAD, more and more elderly 
patients are referred to the cardiology department for diagnostic work-up. In the 
elderly patient population, the diagnosis of CAD is challenging because ischemic 
symptoms are often atypical. Also, the proportion of female patients is much higher 
in this population and it is known that by the age of 75, rates for coronary 
morbidity and mortality are similar in men and women 5.  
Because of the high prevalence of CAD and the atypical symptomatology in the 
elderly, accurate non-invasive techniques are needed in this population to identify 
patients with significant CAD. Stress testing in combination with myocardial 
perfusion imaging (MPI) is routinely used in the elderly patient to assess CAD. Since 
the mid-nineties, there is an increased use of technetium-99m labelled perfusion 
agents, like sestamibi and tetrofosmin, with more favourable imaging 
characteristics compared to 201-thallium. This makes it possible to perform 
electrocardiogram gated single photon emission computed tomography (SPECT) 
during the acquisition of myocardial perfusion 6, which does not only improve the 
specificity for the detection of CAD 7, but also enables the assessment of left 
ventricular (LV) functional parameters including LV ejection fraction (LVEF) and LV 
volumes 8,9. The LVEF is known as one of the most powerful prognostic parameters 
10-12, but also cardiac volumes provide important prognostic information in middle-
aged CAD patients 13-14. Therefore, perfusional parameters 15-16 and functional data 
seem to be important for prognostic assessment in the elderly patient 17-18. This 
article aims to overview briefly the use of MPI and gated MPI in the elderly patient 
population for diagnostic and prognostic purposes. 
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II. Coronary artery disease in the elderly 
 
In contrast with the middle-aged CAD population, women significantly outnumber 
men in the age group 65 years and older. In the European Union, women represent 
65 % of the population aged 75 years and older (data from EUROSTAT, 2003). 
Death rates due to CAD have increased in women because of a more sedentary 
lifestyle in the elderly age group and a higher prevalence of obesity, diabetes 
mellitus type 2 and hypercholesterolemia 19-20. Data of the Framingham study 
revealed that women present with their first anginal symptoms 10 year later and 
sustain their first myocardial infarction 20 years later than men 21 and, by the age 
of 75, rates for coronary morbidity and mortality are similar in both sexes 5. This 
makes that in contrast with the middle-aged CAD population (40-65 y) the 
proportion of women in the elderly population with suspected CAD is much higher. 
Also, the diagnosis of CAD is more difficult in elderly patients because of atypical 
symptomatology and a higher frequency of co-morbidity. For example, exertional 
angina pectoris is commonly the first manifestation of CAD in middle-aged persons, 
but many elderly patients will not experience any exertional angina because of 
limited physical exercise in daily life. Secondly, other disorder can mask or mimic 
the ischaemic cascade: shoulder pain is frequently diagnosed as degenerative 
disease and epigastric pain as peptic ulcer disease. It has been shown that 20-50 
% of patients >65 years demonstrate silent myocardial ischemia upon stress 
testing 22. The detection of this silent ischemia is important because coronary 
events are twice as common in patients with silent myocardial ischemia versus 
those without ischemia 23. 
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III. Stress testing in the elderly 
 
a) Physical ECG stress testing in the elderly patient 
 
Current ACC practice guidelines advise a simple treadmill test as first choice 
investigation in elderly patients. However, the frequent presence of resting 
abnormalities in the ECG of elderly patients and the high proportion of women 
lowers the value of ECG exercise stress testing in this population 24. Secondly, the 
frequent presence of neurological, respiratory or orthopaedic disorders, makes it 
more challenging to perform adequate exertional stress testing and to achieve 
maximal heart rates. Moreover, left bundle branch block and ventricular-paced 
rhythm, frequently seen in older people, are also established indications for 
pharmacologic stress testing 25. Therefore, ECG stress testing is less useful in 
elderly patients than in the middle-aged population.  
 
b) Stress testing for MPI in the elderly 
 
The high prevalence of asymptomatic multivessel disease in the elderly population 
and the fact that a high proportion of patients above 75 years are not able to 
perform adequate stress testing for MPI renders the application of other stress 
modalities in this patient population necessary. Iskandrian et al. reported that 
SPECT perfusion imaging after submaximal exercise is significantly less sensitive 
than after maximal exercise in detecting CAD and in correctly identifying patients 
with multivessel disease 26. In these patients, it is possible to perform perfusion 
imaging after pharmacological stress using agents such as dipyridamole, adenosine 
or dobutamine. Dipyridamole and adenosine cause vasodilatation in the normal 
coronary arteries more than in stenotic vessels. This creates a coronary steal effect, 
resulting in a relative hypoperfusion of the diseased myocardial area, which is 
visualised by MPI.  
Although achieving at least 85% of predicted maximal heart rate is quite difficult to 
obtain in the elderly due to chronotropic incompetence or the use of β- blockers, 
the majority of elderly patients are still able to perform low-level exercise. 
Therefore it is possible to combine physical and pharmacological stress: physical 
exercise stress is started until exhaustion and followed by infusion of 
pharmacological vasodilator stress agents (dipyridamole or adenosine). The 
addition of pharmacological vasodilators to submaximal stress testing does not only 
improve the diagnostic ability of the stress test 27, it also improves image quality 
and decreases the frequency of side effects compared to using the pharmacological 
stressors alone 28-30. Although the use of vasodilators is relatively safe, it must be 
noted that the use of adenosine or dipyridamole is contraindicated in patients with 
active bronchospasm, acute coronary syndrome, hypotension, grade II-III 
atrioventricular block, sick sinus syndrome and sinus bradycardia, situations 
frequently seen in elderly 31. It should be noted that one should not add low-level 
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exercise to patients with left bundle branch block, as they are susceptible to the 
same false positive findings in the interventricular septum as would be seen with 
exercise. As an alternative to vasodilator stress, it is possible to use dobutamine, a 
synthetic catecholamine, as stress agent. The infusion of dobutamine increases 
heart rate and myocardial contractility, resulting in an increased cardiac output. 
This causes an increase in myocardial oxygen demand and blood flow of the normal 
vessels 32. The chronotropic effect of dobutamine is however suboptimal and 
therefore the target heart rate might not be reached 33. In this case, atropine 
addition can increase the heart rate and the sensitivity for detection of ischemic 
heart disease without increasing the side-effects 34,35. Contraindications for 
dobutamine infusion include severe hyper- and hypotension, a recent dissection of 
the aorta or coronary arteries, uncontrolled atrial fibrillation or atrial flutter and 
recurrent ventricular tachycardia. Dobutamine can not be used as a stress agent for 
MPI in patients with left bundle branch block because this may result in false 
positive findings in the interventricular septal wall. 
 
IV. Diagnostic accuracy of stress MPI in the elderly 
 
Radionuclide perfusion imaging combined with exercise or pharmacological stress 
testing demonstrated a high diagnostic accuracy in the detection of CAD in the 
middle-aged patient 36,37. MPI has also been shown to have a good accuracy in the 
elderly. Lam et al. reported similar sensitivities and specificities for 201-thallium 
dipyridamole imaging in patients aged 70 years or above versus younger patients 
38. More recently, Gentile et al. investigated the accuracy of bicycle stress-rest MPI 
using 201-thallium in 132 patients aged >65 years who were hospitalised because 
of cardiac events (angina, dyspnoea, cardiac rhythm disturbances and atypical 
chest pain) using subsequent coronary angiography as a gold standard 39. In this 
study a lesion on coronary angiography was considered significant if ≥ 60% of the 
lumen diameter was obstructed. The diagnostic accuracy of MPI in this study was 
86.3% with a sensitivity of 93.5% and a specificity of 54.1%. The use of 
technetium-99m based myocardial imaging agents with more favourable imaging 
characteristics resulting in less attenuation and scatter, has improved the specificity 
and diagnostic value of SPECT imaging in women 40. Wang et al. studied 75 
consecutive patients aged >80 years who underwent a coronary angiography 
within 6 months of MPI using technetium labelled sestamibi. Overall sensitivity for 
detection of a >75% stenosis was 95% with a specificity of 75% and results were 
similar for pharmacological and exercise stress  MPI 41. 
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V. Risk stratification by MPI in the elderly 
 
a) Prognostic value of myocardial perfusion assessment 
 
Multiple studies investigated the prognostic value of MPI in patients with known or 
suspected CAD for predicting cardiac events and cardiac mortality 42-47. These 
studies demonstrated the prognostic or incremental prognostic value of MPI above 
clinical variables in middle-aged patient populations with known or suspected CAD. 
Exercise MPI has significant added value for risk stratification in CAD, but most 
studied patients have been middle-aged or younger 48,49. Iskandrian et al. studied 
499 patients with CAD aged 60 years or older using exercise thallium-201 planar 
imaging and found a prognostic value for MPI in the prediction of future cardiac 
death or non-fatal myocardial infarction 15. Steingart et al. investigated 578 patients 
aged 65 years or older with interpretable electrocardiograms who were able to 
perform exercise testing with MPI (99m-technetium ligands and 201-thallium) 50. 
During a 4.4±1.3 year follow-up, there were 39 deaths and 17 non-fatal myocardial 
infarctions. In this study population, the assessment of stress-induced ischemia 
provided only limited prognostic information above clinical parameters in the 
prediction of all-cause death and myocardial infarction.  
More recently, Schinkel et al. investigated 272 patients aged > 65 years with 
limited exercise capacity using dobutamine tetrofosmin SPECT and found that the 
summed stress score and abnormal myocardial perfusion (fixed or reversible) 
provided incremental information over clinical data in the prediction of all-cause 
mortality, cardiac death and the combined end point of non-fatal myocardial 
infarction or cardiac death 51.  
Due to aging of the general population, a patient population above 60 or 65 years 
cannot be considered a really elderly population. In a study by Shaw et al. 
investigating 348 patients aged older than 70 years who underwent dipyridamole 
planar thallium-201 perfusion imaging, an abnormal perfusion scan was the best 
predictor of cardiac events (cardiac death or non-fatal myocardial infarction) 16. 
Similar findings were reported by the same group in 120 patients older than 70 
undergoing exercise planar thallium-201 perfusion imaging 52.  
The first study investigating the prognostic value of MPI in a large population (328 
patients) aged 75 years or older with suspected CAD was performed by Lima et al. 
53. In this population, there were 24 cardiac deaths during a 34±15 months follow-
up time. These authors found that an abnormal myocardial perfusion scan (either 
fixed or reversible) was an independent predictor of cardiac death.  
More recently Valeti et al. reported on the prognostic value of thallium-201 
perfusion imaging in 247 patients aged 75 years or older 54. They found that a 
higher summed stress score provided incremental information above clinical 
parameters. A higher summed difference score, ventricular enlargement (graded 
subjectively as present or absent) and increased uptake of thallium-201 in the 
lungs were univariate predictors of cardiac death or myocardial infarction, but these 
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parameters did not prove any incremental value once the summed stress score was 
entered in the multivariate analysis. 
One of the most striking aspects of using MPI as a prognostic tool is the extremely 
low risk in patients with normal scintigraphic images 45,55,56. Many clinical studies 
have demonstrated that patients with normal myocardial perfusion images have a 
very low cardiac event rate (< 1% cardiac deaths/ year). Even when exercise ECG 
(ST depression) or angiographic (multivessel disease) markers of poor outcome are 
present the prognosis in patients with normal MPI is benign 57,58 and these findings 
seem to be similar in the elderly population 39,50. In the study by Steingart et al. in 
578 patients aged 65 years or older with interpretable electrocardiograms who 
underwent exercise testing with MPI, normal scan findings were associated with a 
good prognosis (97% 3-year event free survival rate) 50. 
 
b) Prognostic value of LV dilatation at stress 
 
The TID (transient ischemic dilatation ratio = ungated volume post stress/ ungated 
volume at rest imaging) ratio is a marker for the transient enlargement of the left 
ventricle after stress. It is most commonly known for its diagnostic power as a 
marker of ischemia 59. However, also the prognostic value of a high TID ratio has 
been extensively investigated in middle-aged patient populations with CAD 59-61. In 
the study by Steingart et al. which is already discussed above, ventricular dilatation 
post stress was strongly predictive of future death or non-fatal myocardial 
infarction 50. These findings were confirmed by Valeti 54 and by our group 62. 
 
c) Prognostic value of left ventricular functional parameters 
 
Multiple studies demonstrated the prognostic value of LV functional parameters 
using gated radionuclide angiography 12,63,64, X-ray angiography 13, 
echocardiography 65-68 and even cardiac magnetic resonance 69 in the middle-aged 
population. Using gated SPECT, Sharir et al. found that post stress LVEF and post 
stress LV end-systolic volume assessed during gated SPECT had incremental value 
above clinical parameters in predicting cardiac death 70. Functional data assessed 
during echocardiography have shown prognostic value in elderly patients 71,72. 
However, there is only one report regarding the prognostic value of combined 
perfusion and function imaging assessed by myocardial gated SPECT in the elderly. 
Over the period 1998-2002, we evaluated 294 consecutive patients aged 75 years 
or more (mean age 78±3 years) with suspected or known CAD using stress-rest 
myocardial gated SPECT and followed these during a median follow-up of 25.9 
months 62. We found that LV functional data (LVEF and LV volumes) provided 
independent and incremental prognostic information above clinical and SPECT 
perfusion data for cardiac and all-cause mortality in these patients. More 
importantly, we found that LV functional measurements provided by gated SPECT 
provided a higher predictive value than myocardial perfusional parameters in the 
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prediction of future cardiac death or total mortality. The strongest predictor of total 
mortality in our population was a lower LVEF (Χ2 = 16.9; p<.001) where a higher 
resting LV end systolic volume was the strongest predictor of cardiac mortality (Χ2 
= 24.4; p< .001). Additionally, when comparing post stress and resting functional 
parameters, we found that their prognostic values were comparable. This could be 
expected because the correlation between resting and post stress parameters was 
very high (.91 for LVEF’s and .96 for LV end-systolic volumes). Therefore, when 
functional data are only obtained during stress imaging, these data can be used for 
prognostic stratification instead of the resting data.  
A brief overview of these prognostic studies is provided in the table. 
 
VI. Conclusions 
 
The increasing number of elderly patients requiring diagnostic and prognostic 
assessment for coronary artery disease has necessitated accurate, non-invasive 
techniques applicable to this age group. Exercise testing, either alone or with 
perfusion imaging, remains a useful tool in elderly patients capable of performing 
vigorous treadmill or bicycle exercise. Fortunately, for the large elderly subset 
incapable of such exercise, pharmacologic stress testing with dipyramidole, 
adenosine, or dobutamine offers an excellent alternative. Furthermore, recent data 
support a prognostic approach to the management of middle-aged patients with 
coronary artery disease based on the results of gated myocardial perfusion SPECT 
imaging. Similar in the elderly, the assessment of LV function adds further to the 
diagnostic and prognostic relevance of this imaging modality. This further provides 
significant independent information in the prediction of future cardiac death or all-
cause mortality, especially in a patient population with multiple co-morbidities. 
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TABLE 
 
Abbreviations in the table 
 
ESV: end systolic volume 
EDV: end diastolic volume 
FU: follow-up 
LV: left ventricular 
MI: myocardial infarction 
n: number 
pts: patients 
SDS: summed difference score 
SRS: summed rest score 
SSS: summed stress score 
201-Tl: 201-thallium 
99m-Tc: 99m-technetium 
y: years 
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Abstract 
 
Aim: Amino-terminal pro Brain Natriuretic Peptide (Nt-proBNP) is a valuable tool in 
the diagnosis of heart failure and has a prognostic value in coronary artery disease 
(CAD) patients. Clinical parameters, kidney function and parameters derived from 
gated myocardial perfusion imaging also have shown strong prognostic value in 
these patients. Our study aim was to assess independent determinants of Nt-
proBNP in elderly patients with stable CAD. 
Methods: We studied 247 consecutive patients (198 males and 49 females) with 
stable CAD referred for myocardial perfusion imaging aged ≥ 60 years (mean age 
71±6 years). Left ventricular (LV) volumes were derived from myocardial gated 
SPECT data. Summed stress, rest and difference scores (as marker for myocardial 
ischemia) were calculated using semi-quantitative 4DM gated SPECT software 
(Michigan University). Glomerular filtration rate (GFR) was calculated with a 
validated equation based on serum creatinine level. A linear regression model was 
used to determine independent predictors of log Nt-proBNP.  
Results: Univariate predictors of a higher Nt-proBNP in the study population were 
higher age (p<.001), lower body mass index (p= .026), lower resting systolic blood 
pressure (p= .009), longer QRS duration (p= .024), presence of a left bundle 
branch block on the ECG (p=.005), lower GFR (p<.001), higher resting and post-
stress end-diastolic and end-systolic (ESV) volumes (all p<.001), lower resting and 
post stress ejection fractions (both p< .001), higher summed difference scores (p= 
.026) and higher summed stress and rest scores (all p< .001). A higher post stress 
LV end-systolic volume (ESV) (F = 106.1; p< .001), a lower GFR (F change= 40.3; 
p<.001) and a higher age (F change= 9.3; p= .002) were the only independent 
determinants of Nt-proBNP by multivariate regression analysis. 
Conclusion: A higher post stress LV ESV, a worse kidney function (assessed by 
GFR), and increasing age are independent determinants of Nt-proBNP in elderly 
patients with stable CAD. In contrast, Nt-proBNP levels were not associated with 
myocardial ischemia in multivariate analysis. 
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Introduction 
 
Coronary artery disease (CAD) is the most common cause of heart failure in the 
Western world, accounting for 60-70 % of the cases 1. Incidence and prevalence of 
congestive heart failure due to CAD are increasing worldwide as a result of 
increasing life expectancy in general and the longer survival of patients with CAD in 
particular 2. The increasing prevalence of congestive heart failure has resulted in 
the need for improved therapeutic agents together with simple diagnostic screening 
tools. Brain Natriuretic Peptides (BNP) are neurohormones synthesized by and 
released from cardiac myocytes in response to an increased wall stress. In patients 
with failing hearts, peptide production increases and becomes more generalized 
throughout the myocardium 3. Amino-terminal pro Brain Natriuretic Peptide (Nt-
proBNP), an inactive fragment of BNP, is a valuable tool in the diagnosis of heart 
failure 4,5 and has prognostic value in CAD patients 6,7. Clinical parameters such as 
kidney function and data derived from gated SPECT have however also a strong 
prognostic value in this patient population 8-11. Our study aim was to investigate 
which clinical and gated single photon emission computed tomography (SPECT) 
parameters independently determine Nt-proBNP levels in elderly patients with 
stable CAD. 
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Methods 
 
Study population 
 
The study population consisted of 247 consecutive Caucasian patients aged 60 
years or older with documented CAD. All patients underwent a 2-day stress-rest 
myocardial gated SPECT investigation in the period October 2001- July 2005. The 
diagnosis of ischemic heart disease was based on a history of myocardial infarction, 
percutaneous coronary intervention, coronary artery bypass grafting or 
angiographic significant CAD (at least one coronary artery with ≥ 75 % stenosis).  
There had to be at least 3 months between infarction or revascularisation and 
inclusion in the study. 
 
Nt-proBNP 
 
Patients came to the laboratory for venous blood samples between 8 and 9 AM and 
had been fasting for at least 12 hours. Venous blood was drawn from an 
antecubital vein into gel filled tubes at rest. The specimens were centrifuged within 
1 hour and plasma was frozen at –80° C until analysis. Concentration of Nt-proBNP 
in serum was measured on an ElecsysTM 2010 apparatus (Roche Diagnostics, 
Mannheim, Germany) with an automated electrochemiluminescence sandwich 
immunoassay that uses two polyclonal antibodies directed against residues 1-21 
and 39-50 of the molecule.  
 
Renal function 
 
Serum creatinine was determined by a rate-blanked compensated Jaffé method 
using commercial reagents (Roche, Mannheim, Germany) on a Modular P analyzer 
(Hitachi, Tokyo, Japan). Renal function was assessed by entering this serum 
creatinine value in a validated equation to calculate the estimated glomerular 
filtration rate (GFR). For male patients we used the formula 186 x [(serum 
creatinine level (in mg/dl)] –1.154 x [age (in years)] –0.203. For female patients a 
correction was made by multiplication with 0.742 12,13. 
 
Clinical data 
 
Demographic data were collected at study entrance. All the investigated clinical 
variables are shown in table 1. Blood pressure was measured at rest with a 
calibrated mercury sphygmomanometer. Diabetes mellitus was defined as a fasting 
blood glucose level > 126 mg/ dl and/or the need for insulin or oral antidiabetic 
agents. Body mass index was calculated by the formula: weight (kg)/ square length 
(m2).  
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Gated SPECT acquisition 
 
Stress and rest studies were performed in a 2-day protocol. In both stress and rest 
studies, 900 MegaBecquerel (25 milliCurie) of 99m-technetium sestamibi was 
injected intravenously. Imaging was started between 30-60 minutes after injection 
in the resting state and 15-30 minutes after injection at peak stress. A gated SPECT 
acquisition was performed over 360° in step-and-shoot mode (120 sectors of 3°, 30 
seconds/ step, matrix size 64 x64) using a triple-headed camera (Picker Prism 
3000, Marconi, Philips, Cleveland, Ohio) equipped with low energy all-purpose 
collimators. Acquisitions were gated for 16 frames per cardiac cycle.  
 
Calculation of global LV parameters 
 
The raw gated SPECT data were reconstructed using filtered back projection (ramp 
filter) over 180° and post-filtered using a low pass filter (order 5, cut-off frequency 
.21). The left ventricle was reoriented manually to obtain short axis images, which 
were processed using Quantified Gated SPECT software (QGS®, Cedars-Sinai, Los 
Angeles, CA, USA) to obtain resting LV ejection fraction and LV volumes. The 
automatic myocardial border detection by QGS® was visually inspected and 
corrected if necessary. 
 
Scoring of the perfusion images 
 
For perfusion scoring, the raw gated SPECT data were ungated and reconstructed 
using filtered back projection (ramp filter) and post-filtered using a low pass filter 
(order 5, cut-off frequency .21). The left ventricle was reoriented manually to 
obtain short axis images. These ungated short axis images were used for semi-
quantitative analysis of myocardial perfusion using 4D-MSPECT® software 
(University of Michigan, Ann Arbor, Mi, USA). Myocardial perfusion in stress and 
rest were compared to a gender specific normal perfusion database generated at 
our institution. Stress and rest normal database files were made out of patients 
with a low cardiac risk (< 5 %) 14. Summed stress, summed rest and summed 
difference scores were automatically generated by the software. Summed stress 
and rest scores can be considered as global myocardial perfusion scores in stress 
and rest respectively. The summed difference score is calculated by subtracting the 
summed stress from the summed rest score and is a marker of myocardial 
ischemia. Automatic myocardial border detection by the software was visually 
inspected and corrected if necessary. Semi-quantitative scoring was used instead of 
visual scoring because this makes perfusion scoring more reproducible and less 
dependent on the experience of the observers.  
 
The study was approved by the local Ethics Committee of the Ghent University 
Hospital. All included patients gave informed consent prior to the study.  
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Statistical analysis 
 
Statistical analyses were performed using SPSS 11.0.1 statistical software (SPSS 
Inc., Chicago, USA). As Nt-proBNP values were not normally distributed, they were 
logaritmised for further statistical analysis. Patients were categorized in quartiles 
according to the Nt-proBNP value. Univariate clinical and SPECT predictors of log 
Nt-proBNP were analysed using non-parametric Kruskal-Wallis testing. Univariate 
determinants of log Nt-proBNP significant at the 0.05 level were inserted in a 
forward stepwise multivariate regression model to determine independent 
determinants of log Nt-proBNP. Data are shown as mean ± standard deviation or 
percentage. 
 
Results 
 
Clinical cha acteristics and univariate determinants of Nt-proBNP r
 
Clinical characteristics (table 1) and gated SPECT parameters (table 2) for the 
whole group are given in the tables. Patients were divided in 4 groups according to 
Nt-proBNP quartiles. In this population of elderly patients with stable CAD, 134 had 
a history of myocardial infarction, 91 a history of percutaneous coronary 
intervention and 127 a history of coronary artery bypass grafting. Cardiac 
medications included aspirin (n= 183), beta-blockers (n= 181), angiotensin-
converting enzyme inhibitors or angiotensin-II antagonists (n= 159) and statins 
(n=152). 
A higher age (p<.001), a lower body mass index (p= .026), a lower resting systolic 
blood pressure (p= .009), a longer QRS duration (p= .024), the presence of a left 
bundle branch block on the ECG (p=.005), a lower GFR (p<.001), higher resting 
and post-stress end-diastolic and end-systolic (ESV) volumes (all p<.001), lower 
resting and post stress ejection fractions (both p< .001), higher summed difference 
scores (p= .026) and higher summed stress and rest score (all p< .001) were 
univariate determinants of higher Nt-proBNP (see tables). 
 
Multivariate regression analysis 
 
A higher post stress LV ESV (F = 106.1; p< .001), a lower GFR (F change= 40.3; 
p<.001) and a higher age (F change= 9.3; p= .002) showed to be independent 
determinants of log Nt-proBNP in a multivariate regression analysis model. The 
figure shows mean log Nt-proBNP levels in function of GFR (divided on the 
median= 72 ml/ min) and post stress LV ESV (divided in tertiles: tertile 1: ≤ 37 ml, 
tertile 2: 38- 69 ml, tertile 3 ≥ 70 ml). Summed difference scores did not appear to 
be multivariate determinants of log Nt-proBNP levels. 
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Discussion 
 
The present study shows that renal function, post stress LV ESV and age are 
independent determinants of Nt-proBNP in CAD patients aged 60 years or above. 
Therefore, these parameters must be taken into account when interpreting Nt-
proBNP values in this population. No significant relationship was found between 
summed difference scores and Nt-proBNP levels. 
 
Determinants of BNP in healthy people 
 
In healthy people, increasing age, female gender and a lower heart rate have been 
shown to be associated with higher serum BNP levels 15,16 and Nt-proBNP levels 
17,18. Even in our study population, focused on the elderly, there was a clear 
relation between increasing age and higher Nt-proBNP levels. However, we did not 
find a significant relation to gender and heart rate. 
 
Relationship between extent of CAD and Nt-proBNP values. 
 
In a younger patient population, other groups showed a significant relation 
between Nt-proBNP levels and the extent of CAD 19-21. Because of the invasiveness 
of the procedure, a coronary angiography was not performed routinely in our study 
population. However, we found also a strong univariate relation between the extent 
of CAD (determined by the summed perfusion scores) and Nt-proBNP with worse 
myocardial perfusion scores in patients in the upper Nt-proBNP quartiles. Left 
ventricular functional and perfusion parameters are however closely related in CAD 
patients and our data suggest that once LV functional variables are inserted in the 
multivariate regression model, there is no additional value for myocardial perfusion 
scores for the prediction of Nt-proBNP values in the elderly patient population.  
In contrast, since brain natriuretic hormones are synthesized by and released from 
cardiac myocytes and because there is an increased peptide production in failing 
hearts, higher cardiac volumes are intrinsically related to higher serum Nt-proBNP 
values 4,5,22,23. This is in concordance with data by Sharir et al. where cardiac 
volumes are associated with a worse prognosis 10. In this study there was however 
no BNP or Nt-proBNP determined. 
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Relationship between myocardial ischemia and Nt-proBNP values 
 
In a younger patient population, Weber et al. found a significant univariate 
association between resting Nt-proBNP values and ischemia detection 19. Bibbins-
Domingo et al. showed in a multivariate analysis that resting BNP values were 
higher in CAD patients with inducible ischemia versus those without 24. 
However, in our population aged > 60 years, there was only a relationship between 
ischemia detection and Nt-proBNP levels in univariate analysis (higher summed 
difference scores in patients with a higher Nt-proBNP). Once age, LV ESV and GFR 
were known, there was no significant relationship between the summed difference 
scores and Nt-proBNP values. Our data therefore suggest that ischemia as 
determined by myocardial perfusion imaging is not an independent determinant of 
Nt-proBNP in elderly patients with CAD.  
In the recent literature there is more and more evidence that myocardial ischemia 
can cause an increase of BNP values at stress 25. The specificity of an increased 
BNP in stress for the detection of ischemia is however questionable since physical 
stress can increase BNP values even in the absence of myocardial ischemia 26. Since 
our measurements of Nt-proBNP, like in most large studies investigating the 
diagnostic value of BNP measurements, were made at rest, it is not possible to 
make a comparison with studies where stress BNP values were taken.  
 
BNP or Nt-proBNP and renal failure 
 
Impaired renal function is one of the major risk factors in CAD patients 12 and in the 
elderly patient population 27. It is known that BNP levels increase in patients with 
impaired renal function 28,29. Nt-proBNP is predominantly excreted by the kidneys 
and impaired renal function is common in CAD patients aged 60 years or above 30. 
Therefore it is especially in these patients of importance to determine renal function 
when interpreting BNP values. 
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Prognostic value of BNP or Nt-proBNP in the elderly population 
 
Nt-proBNP levels increase with age in the general population Therefore, higher cut-
off values for Nt-proBNP levels are needed in elderly patients. Wendelboe et al. 
showed that even in patients aged > 75 years, high Nt-proBNP plasma levels are 
predictive of major adverse cardiac events when a higher threshold is used 31. By 
ROC curve analysis, a 3-fold higher cut point had to be used in elderly patients than 
in patients under the age of 75 years. Even in patients aged > 80 years 32 and > 85 
years 33, BNP has shown predictive value for major cardiac events. In a recent 
article, Galasko et al. determined normal values and cut-off values for the detection 
of CAD and heart failure 34. Based on Nt-proBNP levels in healthy people aged ≥ 60 
years, cut-off values of 172 pg/ ml for men and 225 pg/ ml for women are 
proposed in this article. We found however 'normal' Nt-proBNP values following the 
criteria of Galasko et al. in as much as 29 % of the men and 43 % of the women in 
an elderly patient population with known CAD and a mean age of 71 years. 
Therefore, in the knowledge that CAD is frequently present in the elderly, our data 
suggest that the negative predictive value of 'normal' Nt-proBNP levels for the 
detection of CAD is rather low in this population. 
 
 
Conclusions 
 
The present study shows that renal function (assessed by GFR), post stress LV ESV 
and age are independent determinants of Nt-proBNP in CAD patients aged 60 years 
or above. However no significant relationship was found between myocardial 
ischemia and Nt-proBNP levels. 
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Tables 
 
Abbreviations in the tables 
 
DBP: diastolic blood pressure 
GFR: glomerular filtration rate 
HR: heart rate 
LBBB: left bundle branch block 
LVEDV: left ventricular end diastolic volume 
LVEF: left ventricular ejection fraction 
LVESV: left ventricular end systolic volume 
n: number 
Nt-proBNP: amino-terminal pro brain natriuretic peptide 
RBBB: right bundle branch block 
SBP: systolic blood pressure 
SDS: summed difference score 
SRS: summed rest score 
SSS: summed stress score 
y: years 
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Table 1 
 
Clinical Characteristics according to Nt-pro BNP levels 
 
 
All 
patients 
n= 247 
Quartile 1 
n= 61 
Quartile 2 
n= 62 
Quartile 3 
n= 62 
Quartile 4 
n= 62 P 
range Nt-proBNP 26-7775 26-153 156-319 321-706 713-7775  
mean Nt-proBNP 
(pg/ ml) 646±958 92±34 222±47 494±108 1767±1377 <.001 
mean Log Nt-proBNP 
(pg/ ml) 2.53±0.48 1.93±.19 2.34±.90 2.68±.95 3.16±.26 <.001 
Age (y) 71 ± 6 68 ± 6 71 ± 6 70 ± 5 73 ± 5 <.001 
Male gender 80 % 79 % 79 % 81 % 82 % .958 
BMI (kg/ m2) 27.6±5.1 29.1±4.7 27.9±4.4 27.0±4.2 26.8±4.7 .026 
Diabetes 30% 30% 35% 27% 29% .784 
resting HR (beats/ min) 63±13 62±11 61±11 62±14 65±15 .534 
Resting SBP (mm Hg) 145±24 145±23 152±22 139±23 144±25 .009 
Resting DBP (mm Hg) 78±13 78±14 78±11 77±12 77±15 .782 
QRS duration (ms) 100±32 94±26 95±27 95±26 115±41 .024 
LBBB 5% 0% 2% 5% 13% .005 
RBBB 5% 5% 3% 6% 6% .831 
GFR (ml/ min 1.73 m2 
body surface area) 73±17 78±5 78±14 73±18 61±16 <.001 
 
Data are expressed as mean ± standard deviation or %. 
 
Univariate clinical predictors of log Nt-proBNP were analysed using ANOVA for continuous and using 
Kruskal-Wallis testing for categorical variables. 
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Table 2 
 
Gated SPECT parameters according to Nt-pro BNP levels 
 
 
All 
patients 
n= 247 
Quartile 1
n= 61 
Quartile 2
n= 62 
Quartile 3 
n= 62 
Quartile 4 
n= 62 P 
resting LVEDV (ml) 126±60 97±30 119±46 125±51 160±84 <.001
resting LVESV (ml) 65±53 38±18 55±39 64±39 101±78 <.001
resting LVEF (%) 53.7±14.5 61.9±9.6 57.1±13.3 52.7±12.6 43.2±15.2 <.001
Post stress LVEDV 
(ml) 132±67 100±30 124±53 138±58 171±91 <.001
Post stress LVESV (ml) 68±60 37±19 56±41 64±39 109±85 <.001
post stress LVEF (%) 54.7±15.1 64.2±10.4 58.4±11.7 52.5±14.2 43.5±15.4 <.001
SSS 9.1±10.0 4.4±6.2 5.8±7.2 11.6±9.9 15.4±12.1 <.001
SRS 7.4±9.1 3.4±5.7 4.7±6.8 8.6±8.8 13.5±11.2 <.001
SDS 2.2±3.3 1.6±2.6 1.6±2.6 3.2±4.3 2.5±3.4 .026 
 
Data are expressed as mean ± standard deviation. 
 
Univariate SPECT predictors of log Nt-proBNP were analysed using ANOVA. 
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Figure 
 
Abbreviations 
 
ESV: left ventricular end systolic volume 
GFR: glomerular filtration rate 
ESV: end systolic volume 
Nt-proBNP: amino-terminal pro Brain Natriuretic Peptide 
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Figure 
 
Relationship between mean log NT-proBNP, GFR and post stress LV ESV 
 
 
 
 
 
 
Figure legend 
 
GFR is divided on the median (=72 ml/ min); post stress LV ESV is divided in tertiles. 
Overall p for the relation between Nt-proBNP values and post stress left ventricular ESV is: 
< .001 in the whole population 
< .001 in patients with GFR below the median 
< .001 in patients with GFR above the median 
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Abstract 
 
Background: Perfusion and functional data obtained during gated SPECT have 
proven prognostic value in the middle-aged patient population. The aim of this 
study was to investigate if perfusion and functional cardiac gated SPECT data have 
prognostic value in patients aged 75 years or older. 
Methods: We studied clinical and gated SPECT predictors of cardiac and all-cause 
mortality in 294 patients with known or suspected coronary artery disease aged 75 
years or older referred for tetrofosmin cardiac gated SPECT imaging. Summed 
perfusion scores were calculated in a 17-segment model using commercially 
available software (4D-MSPECT). Left ventricular functional data were calculated 
using QGS gated SPECT software. 
Results: Median age of the study population was 78 years (range 75-91 years). 
There were 160 males (54%) and 134 females (46%). During a median follow-up 
of 25.9 months (range 1.8-36), 47 patients (16%) died (27 cardiac deaths). In a 
multivariate Cox proportional hazard regression analysis, the summed rest score 
(Χ2-gain= 8.0, p=.009), transient ischemic dilatation index (χ2-gain= 6.3, p=.012) 
and resting left ventricular ejection fraction (Χ2-gain= 7.0, p=.030) were 
independent predictors of all-cause mortality. Summed rest score (Χ2-gain= 8.2, 
p=.004) and resting end-systolic volume (Χ2-gain= 13.7, p=.005) were 
independent predictors of cardiac death.  
Conclusions: This study showed that gated SPECT left ventricular functional data 
assessed during myocardial gated SPECT provide independent and incremental 
information above clinical and perfusion SPECT data for the prediction of cardiac 
and all-cause mortality in patients aged 75 years or older referred for myocardial 
SPECT imaging. 
 
Introduction 
 
Due to aging of the population and better medical and revascularisation treatment 
of patients with coronary artery disease (CAD), more and more elderly patients are 
referred to the cardiology department for diagnostic work-up. Perfusion and 
functional parameters assessed by myocardial gated single photon emission 
computed tomography (SPECT) have incremental prognostic value above clinical 
parameters in patients with known or suspected CAD 1-6. However, these findings 
are based on middle-aged populations and may therefore not be applicable to the 
elderly patient population. The aim of this study was to investigate if perfusion and 
functional data obtained by myocardial gated SPECT are predictive of all-cause and 
cardiac mortality in patients aged 75 years or older. 
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Methods 
 
Study population 
 
Among 2701 patients referred for a 2 day stress-rest gated myocardial perfusion 
SPECT imaging in the period October 1998 until June 2002, all patients aged 75 
years or above were considered for further prospective prognostic follow-up (n= 
307). Follow-up was successful in 294 patients (96 %) and they formed the study 
population.  
 
Stress testing 
 
Bicycle stress testing was used in patients able to perform physical stress (n= 103, 
35%). When a patient was not able to perform maximal bicycle stress, an 
additional intravenous infusion of dipyridamole was given (n= 48, 16%). In 
patients unable to perform physical stress, only intravenous dipyridamole stress 
testing was used (n= 143, 49%). Patients were informed not to consume caffeine-
containing products for 24 hours before testing. Technetium-99m tetrofosmin was 
injected at peak stress. 
 
Gated SPECT Acquisition and reconstruction 
 
The stress and rest studies were performed in a 2-day protocol as described 
previously 7. In both stress and rest studies, 900 MegaBecquerel (25 milliCurie) of 
technetium-99m tetrofosmin was injected intravenously. Imaging was started 
between 30-60 minutes after injection in the resting state and 15-30 minutes after 
injection at peak stress. An ECG-gated SPECT acquisition was performed over 360° 
using a triple-headed camera (Picker Prism 3000, Marconi, Philips, Cleveland, Ohio) 
equipped with a low energy all-purpose collimator. The gated images were 
processed using Quantified Gated SPECT software (QGS®, Cedars-Sinai, Los 
Angeles, CA, USA) to obtain resting and post stress left ventricular ejection fraction 
(LVEF) and left ventricular (LV) volumes. QGS® gated SPECT software was used to 
determine LV functional data because this software has been extensively validated 
for this purpose 8-9.  
The transient ischemic dilatation (TID) ratio was calculated as the ratio of left 
ventricular volumes at stress and rest using the formula: ungated cardiac volume 
post stress/ ungated cardiac volume at rest 10. 
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Scoring of the perfusion images 
 
The raw gated SPECT data were ungated and reconstructed (using filtered back 
projection and a low pass filter of order 5 and cut-off frequency .21). Myocardial 
perfusion was scored semi-quantitatively in a 17-segment model by 4D-MSPECT® 
software (University of Michigan, Ann Arbor, Mi, USA) using the ungated short axis 
images. This software package was used for perfusion analysis because it allows to 
score perfusion data in a standardized 17-segment model corresponding to the 
AHA/ ACC guidelines 11. Summed stress (SSS), summed rest (SRS), summed 
difference scores (SDS) were automatically generated by comparison with a gender 
specific normal perfusion database generated at our institution. These scores can 
be considered global perfusion scores of the left ventricular myocardium during 
stress (SSS) and in resting condition (SRS). The SDS is calculated by subtracting 
the SRS from the SSS and this score reflects the amount of myocardial ischemia. 
Higher scores indicate a worse perfusion. Ischemia was considered significant if the 
SDS score was ≥ 4. The stress and rest normal database files were made of 
patients with a low cardiac risk (< 5 %) 12. Semi-quantitative scoring was used 
because this makes perfusion scoring more reproducible and less dependent on the 
experience of the observers. The prognostic value of semi-quantitative perfusion 
scoring has been shown to be similar to expert visual analysis 13-14.  
Additionally, myocardial perfusion studies were scored visually as normal (= no 
defect or ischemia) or abnormal (fixed or reversible defect). Visual scoring was 
added to allow comparison of our data with previous studies using visual perfusion 
scoring. 
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Clinical data and follow-up 
 
Demographic data were collected at study entrance (October 1998 until June 
2002). Hypertension was defined as a blood pressure ≥ 140 / 90 mmHg or 
treatment with antihypertensive medication. Diabetes mellitus was defined as a 
fasting blood glucose level > 128 mg/ dl or the need for insulin or oral 
hypoglycaemic agents.  
Clinical parameters, perfusion and function myocardial SPECT data were collected 
prospectively for their potential to predict both cardiac and all-cause mortality.  
Follow-up data were collected in the second half of 2003. The investigator was 
blinded to scanning results at the time of follow-up. Information on mortality and 
cause of mortality were obtained by contacting patients’ general practitioners and 
reviewing hospital records. Cardiac death was defined as death caused by acute 
myocardial infarction, refractory congestive heart failure, clinically important cardiac 
arrhythmias and sudden death without another explanation. A standard 
questionnaire was used for follow-up interviews. Follow-up was limited to 36 
months. 
The study was approved by the local Ethics Committee of the Ghent University 
Hospital.  
 
Statistical analysis 
 
All statistical analyses were performed using SPSS 11.0.1 statistical software (SPSS 
Inc., Chicago, USA). Data are shown as median (25-75th percentile) or number (%). 
Mann-Whitney U testing or Chi-square testing was used to assess differences in 
clinical and SPECT variables between survivors and non-survivors. Cumulative 
survival rates as a function over time were obtained by the Kaplan-Meier method. 
Differences in survival were analysed by log-rank testing.  
Clinical predictors of mortality, including age, gender, body mass index, cardiac 
history, cardiac risk factors, cardiac medication and presence of diabetes mellitus 
were tested by univariate analysis. Significant clinical parameters were forced into a 
stepwise multivariate Cox proportional hazards regression model followed by 
perfusion SPECT variables and gated SPECT variables to determine independent 
predictors of both cardiac and all-cause mortality above clinical parameters. 
Significance was set at < .05. 
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Results 
 
At the time of myocardial SPECT imaging 111 patients (38 %) had a history of prior 
myocardial infarction, 44 patients  (15 %) a history of a percutaneous coronary 
intervention and 87 patients (30 %) previously underwent coronary artery bypass 
grafting.  
During a median follow-up period of 25.9 months (range 1.8-36), 47 patients (16 
%) died of which 27 deaths were considered of cardiac origin. In this period, 21 
patients underwent coronary artery bypass grafting and 8 patients had a 
percutaneous coronary intervention. Non cardiac causes (total n= 20) of death 
were infectious diseases (pneumonia or septic shock) (n= 7), malignancies (n= 4), 
cerebro-vascular attacks (n= 3), renal failure (n= 2) and other causes (n= 4). 
 
 
a) All-cause mortality 
 
Clinical cha acteristics in survivors and non-survivors r
 
Patients’ characteristics are summarized in table 1. The median age of the study 
population was 78 years (range 75-91 years) and 160 (54 %) of the 294 patients 
were male. Patients who died during the follow-up period were significantly more of 
male gender (p= .018) and had a higher resting heart rate (p= .001). There were 
no significant differences in survival between patients who underwent a different 
modality of stress testing. 
 
Medical treatment in survivors and non-survivors 
 
At the start of the follow-up period, 152 patients (52 %) were taking beta-blockers 
and 136 (46%) Angiotensin-Converting Enzyme inhibitors or  Angiotensin-II 
antagonists as medical treatment (table 2). Survivors were more often taking beta-
blocker treatment (p= .020) than non-survivors.  
 
Gated SPECT variables in survivors and non-survivors 
 
Resting myocardial perfusion was significantly worse in patients who died during 
the follow-up period. Non-survivors also had a significant worse global left 
ventricular function compared to survivors, which is reflected in lower resting and 
post stress left ventricular ejection fractions and larger cardiac volumes (table 3). 
There was however no significant difference in median SDS score or in presence of 
ischemia in survivors versus non-survivors. 
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Multivariate predictors of all-cause mortality 
 
In a multivariate Cox proportional hazard model, a higher resting heart rate and 
absence of beta-blocker treatment were independent clinical predictors of all-cause 
mortality (Χ2 = 13.9, p <.001). After forcing the resting heart rate and the 
knowledge of beta-blocker treatment into the multivariate Cox regression model, 
additional  predictive information was provided by the SRS (Χ2-gain of  8.0, p=.009) 
and the TID ratio (additional Χ2-gain of 6.3, p=.012).  
In a final step, functional information was added to the model. This showed that 
the resting LVEF provided an additional Χ2 -gain of 7.0 (p=.030) above the clinical 
and perfusion SPECT parameters for the prediction of all-cause mortality.  
All-cause mortality curves for SRS, TID index and resting LVEF are shown in figures 
1-3. For the SRS curve, patients were divided in normal (SRS 0-3), mildly abnormal 
(SRS 4-8) and moderately-severely abnormal (SRS > 8). For the TID index, patients 
were divided on the median. To obtain the resting LVEF curve, patients were 
grouped as followed: normal (LVEF > 45%) mildly depressed LV (LVEF 30-45%) 
and severely depressed function (LVEF < 30%). Annual mortality rates were 
17.4%, 11.1% and 5.1% in patients with a resting LVEF < 30%, 30-45% and > 
45% respectively (p< .0001). This results in a hazard ratio of 3.5 for patients with 
a LVEF < 30% versus those with a LVEF > 45%. 
In fact, the prognostic value of the resting LVEF had a higher predictive value for 
all-cause mortality than either perfusion SPECT or clinical parameters (table 4). 
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b) Cardiac mortality 
 
Univariate predictors of cardiac mortality 
 
The only univariate clinical predictor of cardiac death was a higher age (p= .048). 
Considering function and perfusion SPECT data, univariate predictors of cardiac 
death were a higher SSS, a higher SRS, an abnormal perfusion scan, a lower 
resting and post stress LVEF and larger resting and post stress cardiac volumes 
(table 5). Similar as for all-cause mortality, there was no higher SDS score or more 
frequent presence of ischemia in patients who died from a cardiac cause. 
 
Multivariate predictors of cardiac mortality 
 
In the multivariate Cox proportional hazard model, the SRS (Χ2-gain of 10.3, 
p=.001) and the resting left ventricular end systolic volume (additional Χ2-gain of 
8.9, p=.003) were independent predictors of cardiac death above clinical 
parameters (= higher age, Χ2 = 4.7; p = .031).  
Cardiac mortality curves for SRS and left ventricular end systolic volume are shown 
in figure 4 and 5. For the SRS curve, patients were grouped as discussed above. To 
obtain the end systolic volume curves (figure 5), a cut-off was made on ≤ 70 
versus > 70 ml based on previous prognostic data (1). In a sensitivity analysis 
(ROC-analysis) performed on our data we found that a cut-off point of 60 and 70 
ml gave similar sensitivities. A cut-off of 70 ml resulted however in a better 
specificity than 60 ml (79% versus 73%). The annual cardiac mortality rate was 
10.4% in patients with a resting end systolic volume > 70ml versus 2.3% in those 
with an end systolic volume ≤ 70 ml (p= .002), resulting in a hazard ratio of 4.5. 
The predictive value of the resting left ventricular end systolic volume was clearly 
more predictive of cardiac death than clinical and perfusion SPECT parameters 
(table 6). 
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Discussion 
 
Our data show that functional parameters obtained by gated SPECT provide 
incremental and independent prognostic value above clinical and perfusion SPECT 
parameters in patients aged 75 years or above.  
 
Prognostic value of myocardial perfusion imaging in the elderly patient population 
 
Multiple studies investigated the prognostic value of myocardial perfusion imaging 
in patients with known or suspected CAD for predicting cardiac events and cardiac 
mortality 4,6,15-18. These studies demonstrated the prognostic or incremental 
prognostic value of myocardial perfusion imaging above clinical variables in middle-
aged patient populations with known or suspected CAD.  
Iskandrian et al. found a prognostic value for exercise thallium-201 planar imaging 
in 499 patients aged 60 years or older for the prediction of future cardiac death or 
non-fatal myocardial infarction 19. Steingart et al. investigated 578 patients aged 65 
years or older with interpretable electrocardiograms who were able to perform 
exercise testing with myocardial perfusion imaging (technetium-99m ligands and 
thallium-201) 20. There were 39 deaths and 17 non-fatal myocardial infarctions 
during a 4.4±1.3 year follow-up. They found that ischemia on perfusion imaging 
provided only limited prognostic information above clinical parameters in this 
population. More recently, Schinkel et al. investigated 272 patients aged > 65 years 
and a limited exercise capacity using dobutamine tetrofosmin SPECT 21. In 
concordance with our findings in patients aged > 75 years, the summed stress 
score and an abnormal perfusion scan (fixed or reversible) provided incremental 
information over clinical data in the prediction of all-cause mortality, cardiac death 
and cardiac death or non-fatal myocardial infarction.   
However, due to aging of the general population, a patient population above 60 or 
65 years cannot be considered a really elderly population. Shaw et al. found that an 
abnormal perfusion scan was the best predictor of cardiac events in 348 patients 
older than 70 years who underwent dipyridamole planar thallium-201 perfusion 
imaging 22. Similar findings were reported by the same group in 120 patients older 
than 70 undergoing exercise planar thallium-201 perfusion imaging 23. 
The first study investigating the prognostic value of perfusion imaging a large 
population (328 patients) aged 75 years or older was performed by Lima et al. 24. 
In this study, there were 24 cardiac deaths during a 34±15 months follow-up time. 
Similar to our findings, the authors found that an abnormal myocardial perfusion 
imaging (fixed or reversible defect) was an independent predictor of cardiac death.  
Recently Valeti et al. reported on the prognostic value of thallium-201 perfusion 
imaging in 247 patients aged 75 years or older 25. In concordance with our findings, 
they found that a higher summed stress score provided incremental information 
above clinical parameters. A higher summed difference score, ventricular 
enlargement (graded subjectively as present or absent) and increased uptake of 
 161  
 
PROGNOSTIC VALUE OF GATED SPECT IN THE ELDERLY 
thallium-201 in the lungs were univariate predictors of cardiac death or myocardial 
infarction, but these parameters did not prove any incremental value once the 
summed stress score was entered in the model.   
Gated SPECT imaging was however not performed by any of these previous 
prognostic studies in the elderly. Therefore, our study is unique in the fact that it 
showed that further prognostic stratification is possible by implementing left 
ventricular functional data. 
 
Prognostic value of lef  ventricular functional parameters t
 
Multiple studies demonstrated the prognostic value of left ventricular functional 
parameters using gated radionuclide angiography 26-28, X-ray angiography 29, 
echocardiography 30-33 and even cardiac magnetic resonance 34 in the middle-aged 
population. Using gated SPECT, Sharir et al. found that post stress LVEF and post 
stress LV end-systolic volume assessed during gated SPECT had incremental 
predictive value above clinical parameters in predicting cardiac death 1.  In our 
study post stress LVEF provided similar prognostic information as resting LVEF and 
post stress end-systolic volume similar information as resting end-systolic volume. 
This could be expected because correlation between resting and post stress 
parameters is very high (.91 for LVEF’s and .96 for LV end-systolic volumes). 
Therefore, when functional data are only obtained during stress imaging, these 
data can be used for prognostic stratification instead of the resting data. 
Our study is the first showing that left ventricular functional data obtained by gated 
SPECT provide significant incremental value above clinical and SPECT perfusion 
parameters in predicting all-cause and cardiac mortality in an elderly patient 
population. 
 
Prognostic value of LV dilatation at stress 
 
The TID ratio is a marker for the transient enlargement of the left ventricle after 
stress. It is most commonly known for its diagnostic power 10. However, also the 
prognostic value of a high TID ratio has been extensively investigated in middle-
aged patient populations with CAD 10,35,36. We found similar prognostic value for 
TID in patients aged 75 years or above.  
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Study limitations 
 
Related to the high age, only 103 (35 %) of the 294 patients were able to perform 
maximal bicycle exercise stress. Therefore, a possible prognostic value of nuclear 
imaging variables incremental to parameters obtained during bicycle stress (stress 
electrocardiography changes, maximum workload or blood pressure change) could 
not be assessed. The relative low percentage of patients who underwent maximal 
stress testing in this study might also explain the reason why post stress functional 
parameters provided similar prognostic information as resting functional 
parameters. 
A possible prognostic value of regional wall motion analysis was not performed 
since there is no well-validated software available for this purpose and because 
variability of visual wall motion analysis is high. 
 
 
Conclusions 
 
This study showed that left ventricular functional data assessed during myocardial 
gated SPECT provide independent and incremental information above clinical and 
perfusion SPECT data for the prediction of cardiac and all-cause mortality in 
patients aged 75 years or older referred for myocardial SPECT imaging. 
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Tables 
 
Abbreviations in the tables 
 
ACE-I: Angiotensin converting enzyme inhibitors 
AT-IIA: angiotensine-II antagonists 
BMI: body mass index 
CABG: coronary artery bypass grafting 
ECG: electrocardiography 
LVEDV: left ventricular end diastolic volume 
LVEF: left ventricular ejection fraction 
LVESV: left ventricular end systolic volume 
MI: myocardial infarction  
MPI: myocardial perfusion imaging 
n: number 
PCI: percutaneous coronary intervention 
pts: patients 
SRS: summed rest score 
TID: transient ischemic dilatation ratio  
y: years  
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Table 1 
 
Clinical backgrounds of all patients and comparison between survivors and non-survivors. 
 
 
 Demographics All pts 
(n=294) 
Non-survivors
(n= 47) 
Survivors 
(n= 247) 
P 
Age (y) 78 (76-80) 78 (76-80) 78 (76-79) .255 
Male gender (%) 160 (54%) 33 (70%) 127 (51%) .018 
BMI (kg/m2) 25.5 
(23.4-27.9) 
25.4 
(22.8-28.0) 
25.5 
(23.4-27.9) 
.499 
Known ischemic heart 
disease 
237 (81%) 39 (83%) 198 (80%) .655 
Clinical angina 52 (18%) 7 (15%) 45 (18%) .585 
Hypertension 175 (60%) 26 (55%) 149 (61) .462 
Systolic blood pressure 
(mm Hg) 
140 
(122-160) 
140 
(120-160) 
140 
(125-160) 
.452 
Diastolic blood pressure 
(mm Hg) 
80 
(70-89) 
80 
(70-89) 
80 
(72-88) 
.769 
 
Diabetes mellitus 63 (21%) 14 (29%) 49 (20%) .142 
      
History of MI 111 (38%) 20 (43%) 91 (37%) .460 
History of PCI 44 (15%) 5 (11%) 39 (16%) .365 
Cardiac 
history 
History of CABG 87 (30%) 12 (26%) 75 (30%) .507 
      
Resting heart rate 
( beats /’) 
65 (58-72) 70 (61-80) 63 (56-71) .001 ECG 
Atrial fibrillation/ flutter 37 (11%) 7 (15%) 24 (10%) .290 
 
Data are expressed as median (25-75th percentile) or number (%). 
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Table 2 
 
Medical therapy in survivors and non-survivors 
 
 All pts (n=294) 
Non-
survivors 
(n= 47) 
Survivors 
(n= 247) p 
Aspirin 176 (60%) 27 (57%) 149 (60%) .713 
Aspirin or warfarin 201 (68%) 31 (66%) 170 (69%) .699 
beta-blockers 152 (52%) 17 (36%) 135 (53%) .020 
ACE-I 120 (41%) 21(45%) 99 (40%) .572 
AT-IIA 18 (6%) 2 (4%) 16 (6%) .561 
ACE-I or AT-IIA 136 (46%) 23 (49%) 113 (46%) .688 
ACE-I or AT-IIA or beta-blockers 209 (71%) 32 (68%) 177 (72%) .621 
Diuretics 79 (27%) 17 (36%) 62 (25%) .117 
Spironolactone 34 (12%) 5 (11%) 29 (12%) .829 
Statine 35 (12%) 4 (9%) 31 (13%) .434 
Fibrate 22 (7%) 3 (6%) 19 (8%) .755 
Nitrates 118 (40%) 22 (47%) 96 (39%) .309 
 
 
Data are expressed as number (%). 
 
 170  
 
PROGNOSTIC VALUE OF GATED SPECT IN THE ELDERLY 
Table 3 
 
Gated SPECT variables of all patients and comparison between survivors and non-survivors. 
 
 
All pts 
(n=294) 
Non-survivors
(n= 47) 
Survivors 
(n= 247) P 
Myocardial perfusion     
Summed stress score 4 (0-12) 5 (1-16) 4 (0-11) .112 
Summed rest score 4 (0-10) 7 (3-16) 3 (0-9) .004 
Summed difference score 0 (0-2) 0 (0-1) 0 (0-2) .063 
Ischemia on MPI 46 (16%) 4 (9%) 42 (17%) .142 
Abnormal MPI 165 (56%) 34 (72%) 131 (53%) .015 
TID 1.00 (.93-1.11) 1.06 (.98-1.13) 1.00 (.91-1.10) .015 
Global left ventricular function     
Resting LVEF (%) 56 (43-66) 45 (28-56) 57 (45-68) <.001
Resting LVEDV (ml) 93 (64-131) 117 (66-169) 90 (63-126) .011 
Resting LVESV (ml) 41 (23-71) 56 (32-127) 39 (22-68) .001 
Post stress LVEF (%) 58 (44-69) 47 (31-62) 60 (48-70) <.001
Post stress LVEDV (ml) 95 (68-136) 122 (75-179) 89 (65-126) .002 
Post stress LVESV (ml) 39 (21-75) 66 (35-136) 37 (19-64) <.001
 
 
Data are expressed as median (25-75th percentile) or number (%). 
 
Table 4 
 
Comparison of the predictive value for all-cause mortality of clinical, SPECT perfusion and functional 
parameters. 
 
 
 Parameters Х2 P 
Clinical model  13.9 < .001 
    
Myocardial perfusion SRS 7.0 .008 
 TID 4.1 .037 
    
Functional data Resting LVEF 16.9 < .001 
 Post stress LVEF 16.1 < .001 
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Table 5 
 
Gated SPECT variables in patients who died from a cardiac cause versus those who did not. 
 
 Cardiac death (n= 27) 
No cardiac death 
(n= 267) P 
Defect extent    
Summed stress score 8 (2-17) 4 (0-11) .030 
Summed rest score 8 (4-17) 4 (0-11) .007 
Summed difference score 0 (0-1) 0 (0-2) .464 
Ischemia on MPI 2 (7%) 44 (16%) .217 
Abnormal MPI 21 (78%) 144 (54%) .018 
TID 1.06 (.98-1.10) 1.00 (.92-1.11) .087 
Global left ventricular function    
Resting LVEF (%) 36 (24-56) 56 (45-67) <.001 
Resting LVEDV (ml) 141 (76-233) 90 (63-126) .002 
Resting LVESV (ml) 82 (31-176) 40 (23-68) .001 
Post stress LVEF (%) 35 (28-55) 59 (47-70) <.001 
Post stress LVEDV (ml) 137 (79-232) 90 (67-126) .001 
Post stress LVESV (ml) 87 (35-156) 38 (20-65) <.001 
 
 
Data are expressed as median (25-75th percentile) or number (%) 
 
Table 6 
 
Comparison of the predictive value for cardiac death of clinical, SPECT perfusion and functional 
parameters. 
 
 
 
 Parameters Х2 P 
Clinical model  4.7 .031 
    
Myocardial perfusion SRS 10.9 .001 
    
Functional data Resting LVESV 24.4 < .001 
 Post stress LVESV 20.4 < .001 
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Figures 
 
Abbreviations in the figures 
 
ESV: end systolic volume 
LVEF: left ventricular ejection fraction 
SRS: summed rest score 
TID ratio: transient ischemic dilatation ratio 
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Figure 1 
 
All-cause mortality in function of the summed rest score. 
 
 
 
Kaplan-Meier survival curves according the resting LVEF group: 
a) SRS 0-3 (n= 138, 14 deaths) 
b) SRS 4-8 (n= 69, 13 deaths) 
c) SRS > 8 (n=87, 20 deaths) 
 
Figure 2 
 
All-cause mortality according to the TID ratio. 
 
 
 
 
Kaplan-Meier survival curves according the TID divided on the median: 
a) TID ratio < 1.005 (n= 147, 16 deaths) 
b) TID ratio > 1.005 (n= 147, 31 deaths) 
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Figure 3 
 
All-cause mortality in function of the resting left ventricular ejection fraction. 
 
 
 
Kaplan-Meier survival curves according the resting LVEF group: 
a) LVEF > 45% (n= 207, 22 deaths) 
b) LVEF 30-45% (n= 51, 12 deaths) 
c) LVEF <30% (n=36, 13 deaths) 
 
Figure 4 
 
Cardiac mortality in function of the summed rest score. 
 
 
 
Kaplan-Meier survival curves according the SRS group: 
a) SRS 0-3 (n= 138, 6 cardiac deaths) 
b) SRS 4-8 (n= 69, 8 cardiac deaths) 
c) SRS > 8 (n=87, 13 cardiac deaths) 
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Figure 5 
 
Cardiac mortality in function of the resting left ventricular end systolic volume. 
 
 
 
Kaplan-Meier survival curves according the resting ESV: 
a) ESV ≤ 70 ml (n= 219, 11 cardiac deaths) 
b) ESV > 70 ml (n= 75, 16 cardiac deaths) 
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GENERAL DISCUSSION  
In this discussion, main results of the study findings in this thesis are summarised 
and placed in perspective to findings by other groups. Also future prospects are 
given. 
 
 
Chapter 1 
 
In the first chapter, we investigated relevant technical issues regarding myocardial 
and bloodpool gated single photon emission computed tomography (SPECT) 
imaging. 
 
First, we investigated the day-to day variability of perfusion and global left 
ventricular (LV) measurements assessed by Quantitative Gated SPECT (QGS®, 
Cedars-Sinai, Los Angeles, California, USA) using 99m-technetium tetrofosmin in 
patients with coronary artery disease (CAD) and LV dysfunction. This imaging 
technique is routinely used in these patients for follow-up of myocardial perfusion 
and function over time. The knowledge of the day-to day variability of this 
technique is important since myocardial gated SPECT is routinely used for follow-up 
of changes in LV perfusion and function in these patients. We showed that 
variability of these global indices of cardiac function assessed during gated 
myocardial SPECT is fairly small in this patient population and is comparable to 
other techniques such as cardiac MRI (magnetic resonance imaging). Therefore, 
this imaging technique can be used for the detection of changes global LV 
functional parameters (LV ejection fraction or volumes) in these patients.  
 
Secondly, we investigated the agreement between four software algorithms for the 
calculation of left and right ventricular functional data obtained during gated 
bloodpool SPECT imaging. For LV ejection fraction (LVEF), tomographic 
radionuclide ventriculography techniques were compared with the well-validated 
planar gated bloodpool technique. We found that the LVEF calculated by the four 
algorithms correlated well with planar radionuclide ventriculography (correlation 
coefficients between .71 and .81) and Bland-Altman plotting showed no significant 
trends across the range of LVEF values. Therefore, these algorithms can be applied 
in clinical practice for the determination of LVEF. However, LVEF values are not 
interchangeable between planar and tomographic techniques or between different 
tomographic algorithms. Volume calculations, especially from the right ventricle 
need further validation, mainly with other techniques, such as cardiac magnetic 
resonance before they can be applied in clinical practice. 
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Chapter 2 
 
In chapter 2, we investigated the clinical value of myocardial gated SPECT imaging 
in patients with CAD and LV dysfunction.  
 
First, we investigated the prognostic value of combined perfusion and functional 
imaging using myocardial gated SPECT in these patients. Due to an increased 
survival of CAD patients, the prevalence of congestive heart failure is increasing in 
the general population and in the cardiologist’s practice. Multiple studies have 
investigated the prognostic value of myocardial perfusion imaging (MPI) in subjects 
with known or suspected CAD for predicting future cardiac events and mortality 1-6. 
However, these prognostic data were all collected in patient populations with 
known or suspected CAD and only few data are available regarding the prognostic 
value of MPI in patients with impaired LV function and known CAD. The risk for 
subsequent cardiac events is much higher in this population than in the generally 
investigated populations 7. Therefore, results and risk factors found in other 
populations may not be extrapolated 8. Data on the prognostic value of MPI in 
patients with CAD and LV dysfunction are scarce. We found that the combined 
assessment of function and perfusion using 99m-technetium tetrofosmin gated 
SPECT provided significant and independent predictive information regarding the 
subsequent risk of major cardiac events in 261 patients with CAD and systolic LV 
dysfunction (LVEF ≤40%). The detection of ischemia on MPI was predictive of 
future major cardiac events, however it was not a significant predictor of future 
cardiac death. In concordance with our data, Miller et al. found a higher 
revascularisation rate, but no difference in survival between patients with large 
ischemic defects versus patients with large fixed defects in 214 patients with a 
LVEF <45 % 9. In 156 patients with CAD and a LVEF < 30 %, Sharir et al. also did 
not find a difference in mortality in patients with fixed versus reversible defects 10. 
The unique aspect of our study compared to previous prognostic data are the fact 
that we included resting and post stress gated functional data in our analysis in a 
patient population with CAD and impaired systolic LV function. Our data 
demonstrate that even in this population in which all patients had a depressed LVEF 
and the spreading of LVEF values was narrow, post stress LVEF was highly 
predictive for future cardiac events and provided incremental value in the prediction 
of future cardiac death. As part of a larger study, Sharir et al. investigated a 
subgroup of 277 patients with suspected CAD and a LVEF < 45% using gated 
SPECT and followed these during 19 ± 5 months 11. They concluded that it is 
possible to further risk stratify these patients upon a post stress LV end systolic 
volume with 70 ml as cut-off value. Although the size of our study group was 
comparable and our follow-up was even longer, we did not find an important 
predictive value for cardiac volumes in our study. Only 20 patients (7.8 %) in our 
population with CAD and a LVEF < 40% had a post stress LV end systolic volume < 
70 ml and these patients had no significant lower mortality than those with a LV 
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end systolic volume ≥ 70 ml. In our study group, there was a trend towards a 
higher resting (p= .084) and post stress (p= .010) LV end systolic volume in 
patients with a subsequent hard event (cardiac death or non-fatal myocardial 
infarction). However, once the post stress LVEF was added to the model, there was 
no further predictive value for LV volumes. 
 
Secondly, we investigated the relation between QRS duration, LV volumes and 
localisation of non-viable tissue in patients with CAD and severe systolic LV 
dysfunction (LVEF ≤30%). We found that a prolonged QRS duration (>120 
milliseconds) is present in almost 70% of these patients. This increase in QRS 
duration is clearly related to an increase in LV end diastolic and end systolic 
volumes, indicating more advanced remodelling in these patients. Patients with 
CAD, an increased QRS duration and severe LV dysfunction are possible candidates 
for cardiac resynchronisation therapy. We found however that 30% of these 
patients had substantial non-viable tissue in the inferolateral wall, the region were 
the LV pacing lead is usually placed. Since non-viable tissue is electromechanically 
non-functional, lead placement on non-viable LV wall tissue could lead to ineffective 
pacing in these patients. The high prevalence of non-viable tissue in these patients 
could be one of the explanations why cardiac resynchronisation therapy is 
ineffective in a substantial number of patients with CAD. Further prospective 
studies are however needed to determine whether viability assessment can help in 
the selection of candidates for cardiac resynchronisation treatment and in the 
determination of the optimal lead localisation. 
 
Chapter 3 
 
In chapter 3, we performed studies in the elderly population using myocardial 
gated SPECT imaging.  
 
First, we investigated the determinants of amino-terminal pro Brain Natriuretic 
Peptide (Nt-proBNP) in 247 patients with stable CAD aged 60 years or above. Brain 
natriuretic peptides are neurohormones synthesized by and released from cardiac 
myocytes in response to an increased wall stress. In patients with failing hearts, 
peptide production increases and becomes more generalised throughout the 
myocardium 12. Nt-proBNP is a valuable tool in the diagnosis of heart failure 13,14 
and has prognostic value in CAD patients 15,16. In healthy people, increasing age, 
female gender and a lower heart rate have been shown to be associated with 
higher Nt-proBNP values 17,18. We found that a higher post stress LV end systolic 
volume, a worse kidney function (lower glomerular filtration rate) and a higher age 
were independent predictors of a higher Nt-proBNP in our investigated population 
of CAD patients aged 60 years or above. We found however no significant 
relationship between myocardial ischemia and Nt-proBNP levels. 
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Secondly, we investigated the prognostic value of combined gated SPECT perfusion 
and function imaging in 294 patients aged 75 years or above referred for MPI. We 
showed that LV functional parameters obtained during gated SPECT provide 
significant incremental value above clinical and perfusion SPECT parameters for the 
prediction of cardiac death and all-cause mortality. In fact, functional data assessed 
during gated SPECT had a higher predictive value for cardiac death and all-cause 
mortality than either perfusion SPECT or clinical parameters. Multiple previous 
studies investigated the prognostic value of MPI in elderly patients 19-25. Gated 
SPECT imaging was however not performed by any of these previous prognostic 
studies in the elderly. Therefore, our study was unique in the fact that it showed 
that further prognostic stratification in the elderly is possible by implementing LV 
functional data. 
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Future prospects 
 
The number of patients with CAD and LV dysfunction will further increase during 
the next decade due to aging of the population and better medical and 
revascularisation strategies. Similarly, the proportion of elderly patients referred to 
the cardiology department will continue to grow. This will result in a higher demand 
for non-invasive imaging techniques. These techniques should be accurate, cost-
effective, patient friendly and preferably with low or no radiation burden. 
Gated SPECT imaging has proven diagnostic and prognostic abilities for the 
detection of significant CAD and may prove in the future to be an ideal tool in these 
patients because it allows both the detection of perfusion and functional 
abnormalities and it gives additional prognostic information. Myocardial perfusion 
imaging has proven to be a cost-effective gatekeeper in the management of 
patients with suspected CAD 26. However, due to the aging of the population, 
healthcare demands will continue to rise. Therefore it is necessary that large cost 
effectiveness studies of diagnostic strategies using gated SPECT are compared 
against other imaging modalities in selected patient populations. In the mean time, 
imaging modalities of the heart are improving fast:  
 
-Technical advances in the echo equipment have improved image quality of 
contrast echocardiography (perfusion imaging). Using 3-dimensional 
echocardiography, it is now possible to measure accurate LV volumes 
without the assumption of an ideal ellipsoid structure. Stress 
echocardiography is a radiation free alternative for cardiac imaging of 
myocardial ischemia and is based on the visualisation of wall motion 
abnormal wall motion during or after stress (stunning). 
-Due to its high resolution and because it is free of radiation burden, cardiac 
magnetic resonance has several advantages above other imaging 
techniques. Although it is technically possible to perform both perfusion 
imaging and functional imaging of the left ventricle, cardiac MRI is still time 
consuming. Similar as in stress echocardiography, ischemia imaging by this 
technique is indirect by showing wall motion abnormalities during or after 
stress.  
-Since the development of multislice CT-scanners, CT-angiography is new 
promising tool in clinical cardiology. It allows to visualise the coronary 
anatomy and makes it possible to diagnose CAD in a non-invasive manner. 
Therefore, this tool could become important in risk stratification of 
asymptomatic patients. However, at present time, it does not give 
information on myocardial function or perfusion. 
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-With the increasing availability of positron emission tomography (PET), an 
increasing number of centres are able to perform fluorodeoxyglucose (FDG) 
PET for viability imaging. However, PET perfusion imaging is also becoming 
more available. Previously, PET perfusion studies could only be performed in 
centres with an in-house cyclotron to provide ammonia (13-NH3) or O-
labelled water. Recently, generator based 82-rubidium has been 
commerialised, and this results in an increase in the number of centres 
performing PET perfusion imaging in daily routine. The use of 82-rubidium 
PET is still very expensive (costs of the PET camera and the isotope); 
however, the favourable imaging characteristics, high possible throughput 
(stress and rest imaging possible in 40 min) and the very  low radiation 
burden to the patients (only 2.75 mSv) 27 means that this technique has 
possibilities in the next few years .  
-PET/CT opens possibilities towards a ‘one-stop-shop’ in cardiac imaging; 
however, the complexity of data acquisition, reconstruction and analysis, 
together with the unsolved item of cost effectiveness and radiation exposure, 
need further proof and validation before it can be used in clinical practice.  
-In SPECT imaging, attenuation correction of the images is made easier in 
the daily clinical practice because of the introduction of dedicated cardiac 
SPECT scanners with transmission sources. Also the recent development of 
hybrid SPECT/CT makes attenuation correction easier in the clinical routine 
and offers possibilities for combined visualisation of myocardial perfusion (by 
SPECT) and coronary artery stenosis (by CT angiography). 
 
Recently, new biochemical parameters, such as Nt-proBNP, have also shown 
prognostic value in selected patient populations 15,16. Future studies are needed to 
determine the clinical utility of natriuretic hormones and other biochemical markers 
as compared to different imaging modalities. 
Finally, non-invasive cardiac imaging will continue to grow and the true challenge 
will be to establish the added value of the different techniques in different patient 
populations in a cost-effective manner. 
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SUMMARY  
Prognosis in patients with coronary artery disease (CAD) is determined by clinical 
and biochemical factors, the extent and severity of the CAD and the degree of left 
ventricular dysfunction.  
The major goal of this thesis was to assess the prognostic value of combined 
perfusion and function imaging using myocardial gated single photon emission 
computed tomography (SPECT) in two subgroups of the cardiac population: 
patients with CAD and left ventricular dysfunction and the elderly. 
 
There were three aims: 1) to investigate the variability of gated SPECT techniques 
2) to assess the prognostic value of gated myocardial perfusion imaging in patients 
with CAD and left ventricular dysfunction 3) to assess the prognostic value of gated 
myocardial SPECT in the elderly. 
 
In the first chapter of this thesis, we investigated relevant technical issues 
regarding cardiac gated SPECT imaging.  
First, we investigated the day-to day variability of myocardial perfusion and global 
left ventricular measurements assessed by Quantitative Gated SPECT (QGS®, 
Cedars Sinai, Los Angeles) using 99m-technetium tetrofosmin in patients with CAD 
and left ventricular dysfunction. We showed that variability of global indices of left 
ventricular function (ejection fraction, end systolic and end diastolic volumes) is 
fairly small in this patient population. Therefore, this imaging technique can be 
used for the detection of left ventricular functional changes in these patients. 
Secondly, we investigated the agreement between four software algorithms for the 
calculation of left and right ventricular ejection fraction and volumes obtained 
during bloodpool gated SPECT imaging. We found that the left ventricular ejection 
fraction (LVEF) calculated by these four algorithms correlated well with planar 
radionuclide ventriculography and that there were no significant trends across the 
range of LVEF values. We concluded that, although results from these algorithms 
are not interchangeable, they can be used in clinical practice for calculation of the 
LVEF. Calculation of the right ventricular ejection fraction and volume assessment 
need however further validation before they can be implemented in clinical 
practice. 
 
In the second chapter, we investigated the clinical value of myocardial gated SPECT 
in  patients with CAD and left ventricular dysfunction. 
First, we investigated the prognostic value of combined perfusion and function 
imaging in this population. We found that the combined assessment of perfusion 
and function provides significant independent predictive information regarding the 
subsequent risk of major cardiac events in these patients. Our data demonstrated 
that, even in this population where all patients had a depressed left ventricular 
function and the spreading of the LVEF’s was narrow, post stress LVEF had a high 
predictive value for future cardiac events and provided incremental predictive value 
for future cardiac death. 
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Secondly, we investigated the relation between QRS duration, left ventricular 
volumes and the localisation of non-viable tissue in patients with CAD and severe 
systolic left ventricular dysfunction (LVEF ≤ 30%). We found that the increase in 
QRS duration is clearly related to the increase in left ventricular end diastolic and 
end systolic volumes, indicating a more advanced remodelling in these patients. We 
also found that 30% of the patients with a LVEF ≤ 30% and an increased QRS 
duration have substantial non-viable tissue in the inferolateral wall. This may be 
important since these patients are possible candidates for cardiac resynchronisation 
treatment and because lead placement on non-viable tissue may lead to ineffective 
cardiac pacing. 
 
In the third chapter, we investigated clinical, biochemical, myocardial perfusion and 
function SPECT determinants of amino-terminal brain natriuretic peptide (NT-
proBNP) in the elderly. We found that a higher post stress end systolic volume, a 
worse kidney function and a higher age were independent predictors of a higher 
NT-proBNP in patients with CAD aged 60 years or above. We found however no 
significant relationship between myocardial ischemia and Nt-proBNP levels. 
Secondly, we investigated the prognostic value of combined perfusion and function 
imaging using myocardial gated SPECT in patients aged 75 years or above referred 
for MPI. We showed that left ventricular functional data obtained during gated 
SPECT provide significant incremental predictive value above clinical and SPECT 
perfusion parameters. In fact, functional data had a higher predictive value for 
cardiac death and all-cause mortality than either clinical or perfusion SPECT data. 
Therefore, further prognostic stratification is possible by implementing left 
ventricular functional information in elderly patients undergoing MPI. 
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SAMENVATTING 
De prognose bij patiënten met ischemisch hart lijden (IHL) wordt bepaald door 
klinische en biochemische factoren, de uitgebreidheid en de ernst van het IHL en 
de graad van de linker ventrikel dysfunctie. 
Het belangrijkste doel van deze thesis was het onderzoeken van de prognostische 
waarde van gecombineerde beeldvorming van de doorbloeding (perfusie) en functie 
van de hartspier met behulp van gated SPECT in twee populaties van 
hartpatiënten: 
1) patiënten met IHL en linker kamer dysfunctie 
2) oudere patiënten 
 
Er waren drie vooropgezette doelstellingen 1) het onderzoeken van de variabiliteit 
van gated SPECT technieken 2) het onderzoeken van de prognostische waarde van 
gated myocardperfusie SPECT bij patiënten met IHL en linker ventrikel dysfunctie 
3) het onderzoeken van de prognostische waarde van gated myocardperfusie 
SPECT in de oudere patiënten populatie. 
 
In hoofdstuk 1 onderzochten we de relevante technische vraagstellingen in cardiale 
gated SPECT beeldvorming. 
Vooreerst onderzochten we de dag- tot dag variabiliteit van de meting van de 
myocard doorbloeding en linker ventrikel functie gemeten met behulp van 
Quantitative gated SPECT software (QGS®, Cedars-Sinai, Los Angeles) voor 99m-
technetium tetrofosmin bij patiënten met IHL en linker ventrikel dysfunctie. We 
toonden aan dat de variabiliteit van de globale linker ventrikel functie metingen 
(ejectiefractie, eind-systolische en eind-diastolische volumes) relatief klein is bij 
deze patiënten en dat daarom deze beeldvorming kan gebruikt worden voor het 
opsporen van linker ventrikel functionele veranderingen bij deze patiënten. 
Ten tweede onderzochten we de overeenkomst tussen 4 software algoritmes welke 
gebruikt worden voor de berekening van de linker en rechter ventrikel ejectiefractie 
en volumes tijdens bloodpool gated SPECT beeldvorming. We vonden dat de linker 
ventrikel ejectiefractie (LVEF) berekend met behulp van deze 4 algoritmes goed 
overeenkomt met de planaire isotopen ventrikelbeeldvorming en dat er geen 
significante trends waren over de spreiding van de LVEF waarden. We 
concludeerden hierbij dat deze algoritmes in de klinische praktijk kunnen gebruikt 
worden voor de berekening van de LVEF, maar dat de waarden van de 
verschillende algoritmes niet onderling uitwisselbaar zijn. De berekening van de 
rechter ventrikel ejectiefractie en van volumes moet verder gevalideerd worden 
vooraleer deze in de klinische praktijk toegepast kan worden. 
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In het tweede hoofdstuk onderzochten we de klinische waarde van 
myocardperfusie SPECT bij patiënten met IHL en een linker ventrikel functie 
stoornis. 
Ten eerste onderzochten we de prognostische waarde van gecombineerde perfusie 
en functie beeldvorming bij deze patiënten. We vonden hierbij dat gecombineerde 
meting van perfusie en functie significante voorspellende informatie oplevert met 
betrekking tot toekomstige cardiale events bij deze patiënten. Onze data toonden 
aan dat de LVEF na stress, niettegenstaande de smalle spreiding bij deze patiënten, 
een hoge voorspellende waarde had voor toekomstige cardiale events naast een 
toegevoegde voorspellende waarde voor toekomstige cardiale dood. 
Ten tweede onderzochten we het verband tussen de QRS duur, linker ventrikel 
volumes en lokalisatie van niet-leefbaar weefsel bij patiënten met IHL en een 
ernstige systolische linker ventrikel functie stoornis (LVEF ≤ 30%). We vonden dat 
de toename van de QRS duur duidelijk verband houdt met de toename in de linker 
ventrikel einddiastolische en eindsystolische volumes, wat wijst op een verder 
gevorderde remodellering van het hart bij deze patiënten. We vonden tevens dat 
30% van de patiënten met een LVEF < 30% en een verlengde QRS duur een 
substantiële hoeveelheid niet-leefbaar weefsel hebben ter hoogte van de 
inferolaterale wand. Dit kan van belang zijn bij deze patiënten aangezien ze 
mogelijke kandidaten zijn voor cardiale resynchronisatie behandeling en omdat de 
positionering van de electrodes op niet-viabel weefsel kan leiden tot niet-effectieve 
cardiale stimulatie. 
 
In hoofdstuk 3, onderzochten we klinische, biochemische, myocardperfusie en 
myocardiale functie variabelen welke amino-terminaal brain natriuretic peptide (NT-
proBNP) bepalen in een oudere patiënten populatie. We vonden hierbij dat een 
hoger eind systolisch volume na stress, een verminderde nierfunctie en een hogere 
leeftijd onafhankelijke voorspellende factoren zijn van een hoger NT-proBNP bij 
patiënten ouder dan 60 jaar. Deze factoren moeten dus in rekening gebracht 
worden wanneer NT-proBNP in deze populatie geïnterpreteerd wordt voor 
diagnostische of prognostische doeleinden. 
Ten tweede onderzochten we de prognostische waarde van gecombineerde 
perfusie en functie beeldvorming met behulp van myocardiale gated SPECT bij 
patiënten ouder dan 75 jaar welke verwezen werden voor myocardperfusie 
beeldvorming. We toonden hierbij aan dat de functionele linker ventrikel data welke 
gemeten werden tijdens gated SPECT een significante toegevoegde waarde 
hadden, boven de klinische en myocardperfusie data, voor de voorspelling van 
cardiale en totale mortaliteit. De functionele data in se hadden zelfs een grotere 
voorspellende waarde voor cardiale en totale sterfte dan de klinische of 
myocardperfusie SPECT data. Verdere prognostische stratificatie met behulp van de 
functionele data van het linker ventrikel is dus mogelijk bij deze oudere patiënten 
welke een myocardperfusie scintigrafie ondergaan. 
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after myocardial infarction. De Sutter J, De Winter O, De Bondt P, Van de Wiele C, Dierckx R, 
Tavernier R. 
European Heart Journal 2001, 22: 481 Suppl. S.  
 
Adverse Left Ventricular Remodelling Assessed by 99m-Technetium Tetrofosmin Gated SPECT in 
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51st annual meeting of the Society of Nuclear Medicine, juni 19-23 2004, Philadelphia, J Nucl Med 
2004, 45, 176 Suppl S. 
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Gillebert TC, Bernard D, Langlois M, Dierckx R, De Sutter R. 
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